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Abstract
Dopamine receptors are important G protein-coupled receptors (GPCRs) with therapeutic 
opportunities for treating Parkinson’s Disease (PD) motor and cognitive deficits. Biased D1 
dopamine ligands that differentially activate G protein over β-arrestin recruitment pathways are 
valuable chemical tools for dissecting positive versus negative effects in drugs for PD. Here, we 
reveal an iterative approach toward modification of a D1-selective noncatechol scaffold critical for 
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G protein-biased agonism. This approach provided enhanced understanding of the structural 
components critical for activity and signaling bias and led to the discovery of several novel 
compounds with useful pharmacological properties, including three highly GS-biased partial 
agonists. Administration of a potent, balanced, and brain-penetrant lead compound from this series 
results in robust antiparkinsonian effects in a rodent model of PD. This study suggests that the 
noncatechol ligands developed through this approach are valuable tools for probing D1 receptor 
signaling biology and biased agonism in models of neurologic disease.
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Keywords
Parkinson’s disease; D1 dopamine receptor; noncatechol agonists; dyskinesia; β-arrestins; biased 
agonism; structure–functional selectivity relationship
INTRODUCTION
G protein-coupled receptors (GPCRs) are a superfamily of receptors with seven 
transmembrane helical domains that carry out a large variety of physiological processes. 
With over 800 members capable of carrying out a large variety of physiological processes, 
GPCRs are a critically important class of targets for drug discovery.1 In fact, over 30% of 
FDA-approved drugs target GPCRs and cover a large number of clinical indications. As 
such, GPCRs are one of the most successful and promising target classes for drug discovery.
2,3
Traditionally, GPCRs were thought to conduct intracellular signaling exclusively through a 
canonical G protein-dependent pathway. More recently, the field has moved toward 
appreciating the fact that the GPCR superfamily is actually capable of downstream signaling 
through multiple G protein-independent pathways.4–7 Perhaps the most notable of these 
downstream pathways are the β-arrestin-dependent pathways.8 Signaling through β-arrestin-
dependent pathways typically proceeds when a family of protein kinases called G protein-
coupled receptor kinases (GRKs) phosphorylate the intracellular domains of a GPCR upon 
activation, thereby allowing the phosphorylated GPCR to recruit β-arrestins.9–12 Previously, 
β-arrestins were primarily appreciated for their role in desensitizing G protein signaling by 
interacting with trafficking proteins, such as clathrin, leading to internalization and 
downregulation.13–15 A new paradigm has been developed, however, whereby β-arrestins are 
now also appreciated for their ability to act as signal transducers themselves downstream of 
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GPCRs, with the ability to interact with components of the MAPK cascade,16–19 
nonreceptor tyrosine kinases,20–22 and other signaling pathways that mediate important cell 
biological processes.
With the identification of downstream signaling pathways that operate independent of G 
proteins, such as β-arrestins, it has been shown that these mediators can interact directly 
with GPCRs to stabilize conformationally distinct active states of the receptor.23 
Furthermore, it has been demonstrated that ligands of GPCRs can induce a unique receptor 
conformation that can subsequently lead to preferential activation of a certain downstream 
signaling pathway, a phenomenon termed “functional selectivity” or “biased signaling”.13–19 
Accumulating evidence in this area has propelled the concept of functional selectivity to the 
forefront of the GPCR field, with many studies beginning to explore the structural–
functional selectivity relationships (SFSRs) that may exist between the structural features of 
a ligand that may determine its precise binding mode within a GPCR and its observed 
functional selectivity profile.24–29
Dopamine receptors are important GPCR targets with therapeutic potential in treating motor 
deficits in diseases, such as Parkinson’s Disease (PD), as well as cognitive deficits resulting 
from various neuropsychiatric disorders including Alzheimer’s Disease, PD, and 
schizophrenia.30–33 There are five known subtypes of dopamine receptors that are 
categorized into two subfamilies, the D1-like (D1R and D5R) and D2-like (D2R, D3R, and 
D4R) receptors, which signal through GS or Gi/o G proteins, respectively.9,10,34 Despite their 
effective use in treating several neuropsychiatric disorders, dopaminergic agonists can carry 
certain debilitating motor side effects including dyskinesias, which can compromise patient 
function and quality of life, thereby presenting a considerable limitation to their use in 
diseases, such as PD.35,36 In addition, concerns over clinically significant side effects, such 
as hypotension and tolerance observed following treatment with D1R agonist candidates 
have prevented their approval.37,38 Safer and more effective drugs are needed to not only 
help restore dopaminergic transmission and signaling in these pathophysiological states but 
also to minimize the motor side effects that may result from chronic dopaminergic therapy.
Recent genetic animal studies support the notion that dyskinesias are associated with 
increased G protein signaling and also validate β-arrestin2 as a novel target for treating PD 
without causing dyskinesia. For example, these studies have shown that knocking out β-
arrestin2 in rodent and nonhuman primate models of PD worsened dyskinesias following L-
DOPA administration, while β-arrestin2 overexpression reduced dyskinesias and increased 
locomotion via β-arrestin2 signaling.34 These studies, as well as others in the field that have 
investigated functionally selective signaling at other dopaminergic,24,25,27,39–49 serotonergic,
26,50–53 and opioid receptors,54–67 have shown that through the preferential activation of one 
distinct signaling pathway over another, it is possible to sometimes separate therapeutic from 
adverse effects at a given receptor. Taken together, evidence in the field suggests that 
designing biased ligands may be a novel solution for developing safer and more efficacious 
drugs that retain their therapeutic effects while mitigating the incidence of adverse side 
effects.
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Functionally selective ligands of GPCRs represent valuable chemical tools for elucidating 
the roles of signaling pathways downstream of the receptor. In 2018, Gray et al. disclosed a 
novel noncatechol-containing scaffold that was reported to display potent agonism of D1R.68 
Several properties of this agonist class make it a particularly interesting candidate for 
medicinal chemistry exploration. First, this scaffold was characterized as inherently G 
protein-biased, likely due to its unique putative binding mode within the orthosteric site. 
Mutagenesis work suggests that this scaffold makes contacts with certain residues in the 
orthosteric pocket that are distinctly different from those typically made by catechol-
containing ligands, including dopamine. Second, a 2018 study by Davoren et al., which 
described the high throughput screening campaign that ultimately led to the discovery of this 
noncatechol scaffold, also emphasized the importance of atropisomerism inherent to the 
structure of these ligands.69 Given these interesting findings, this unique scaffold represents 
an excellent opportunity to design novel chemical tools for better understanding the 
structural determinants of D1R agonism and functionally selective signaling.
Previously, we reported a comprehensive SFSR study of this noncatechol D1R agonist 
scaffold.25 Through the systematic modification of four modifiable regions of the scaffold, 
we generated over 50 novel derivatives with diverse functional selectivity profiles. By 
associating certain structural modifications with alterations in functional selectivity, we were 
able to describe several interesting SFSR trends for this scaffold and gain new insights 
regarding which regions of the scaffold were critical for maintaining potency and efficacy in 
both G protein pathway activation and β-arrestin2 recruitment.25
Here, we report our findings from a new exploratory study that takes a significantly different 
approach to ligand discovery from both our previous systematic SFSR campaign and other 
studies reporting noncatechol analogues of D1R. Instead, we utilize the lessons and trends 
learned from previous studies to design novel ligands “from the ground up”. Importantly, 
ligand design using this approach carries the distinct advantage of enabling a better 
understanding of precise structural components that are critical for noncatechol D1 potency, 
efficacy, and signaling bias. As a result of this process, we have discovered several new 
scaffold derivatives with novel pharmacological properties and robust in vivo activity. We 
describe the iterative design, synthesis, and pharmacological assessment of these derivatives 
in both in vitro and in vivo systems. We believe this is a simple, yet powerful approach to 
GPCR ligand discovery with particular relevance to exploration of the structural components 
of a given ligand that are critical to enable biased signaling incorporation into D1 drug 
design.
RESULTS AND DISCUSSION
Previous SFSR studies of the right-hand side (RHS) of the noncatechol scaffold suggest that 
several of its properties are critical to the activity of the overall ligand at D1R.25,68,69 In 
particular, our previous SFSR campaign on the RHS of PF-6142 suggested that factors, such 
as ring size, heteroatom arrangement, and substituent position were of utmost importance in 
maintaining the efficacy and potency of the scaffold in both G protein and β-arrestin2 
pathways. For example, introducing the same imidazopyrazinyl RHS with a different 
methylation position and attachment point significantly diminished potency in both the GS-
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cAMP accumulation and β-arrestin2 recruitment assays while maintaining partial agonism 
in the GS-cAMP accumulation assay. Conversely, omission of the 6-methyl substituent and 
the 7-position nitrogen of the imidazopyrazinyl ring to give an unsubstituted 
imidazopyridinyl ring on the RHS resulted in a compound with only mildly compromised 
potency in the GS-cAMP accumulation and β-arrestin2 recruitment assays but full agonism 
in the Gs-cAMP accumulation assay.25 Our previous investigation also elucidated that 
various monocyclic moieties on the RHS region of the noncatechol scaffold also possessed 
varying degrees of potency and bias relative to the initial bicyclic starting compound.
While these and other findings do implicate the RHS of the noncatechol scaffold as 
important for various pharmacological properties of the ligand, it is difficult to gain 
significant insight into which precise factors are responsible for such effects when the 
ligands comprise part of a diverse set of exploratory modifications, rather than an iterative 
series of carefully implemented changes. To elucidate the critical structural elements of a 
potent RHS moiety on the noncatechol scaffold, we took an iterative approach to building 
the RHS starting from the ground up.
Starting from a very simple monocyclic RHS group, we synthesized a small series of highly 
related structural analogues and determined their in vitro pharmacological properties in both 
stimulating D1R-mediated cAMP production in a D1R-Gs GloSensor assay and in activating 
D1R-mediated β-arrestin2 recruitment in a bioluminescence resonance energy transfer 
(BRET) platform-based assay. Dopamine was included as a positive full agonist control in 
both assays. When interpreting results from these assays, it is also important to consider 
their mechanistic differences as the GloSensor assay involves a signal amplification 
mechanism, while the BRET assay does not, which may have implications in terms of the 
receptor occupancy required to achieve an EMAX in each system. With these considerations 
in mind, compounds from each synthetic iteration were assayed together to infer relative 
changes to structural, spatial, and electronic properties on ligand bias and potency. The 
inferences gleaned from this small series of ligands informed the design of subsequent 
batches of compounds, progressing into compounds with increasingly improved activities 
and diverse functional selectivity profiles. Upon optimization of the RHS, this same 
approach was also applied to the left-hand side (LHS), resulting in several novel compounds 
with interesting pharmacological properties (Figure 1).
Iterative SFSR of the RHS Heterocycle.
To establish a baseline RHS moiety to which we could easily incorporate new structural 
elements, we began with a relatively simple compound (1) and, subsequently, designed and 
synthesized the compounds presented in Figure 2. All of the compounds presented in Figure 
2 were prepared according to the synthetic strategy shown in the first iteration of Scheme 1. 
Briefly, these ligands were prepared by reacting the commercially available chlorinated 
pyridofuran ring with 4-bromo-3-methylphenol to produce the known brominated 
intermediate. Conversion of the brominated intermediate into the known boronic ester 
intermediate68 then enabled a subsequent Suzuki coupling of the boronic ester with a series 
of either custom-made or commercially available brominated heterocycles using catalytic 
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amounts of tetrakis(triphenylphosphine)palladium(0). This strategy afforded the desired 
compounds in good yields.
The ability of each final compound to stimulate D1R-mediated cAMP production and D1R-
mediated recruitment of β-arrestin2 was assessed in vitro using a D1R-GS GloSensor assay 
and a BRET platform-based assay, respectively. Importantly, dopamine was used as a full 
agonist positive control in both assays.70–72
Compound 1, which featured a simple 1-methyl-1,2,3,6-tetrahydropyridin-4-yl, was selected 
as the starting point for this investigation. When tested for both GS-cAMP accumulation and 
β-arrestin2 recruitment, compound 1 was found to be largely inactive in both assays. From 
here, we made several minor modifications to the RHS of 1 to explore the immediate 
chemical space around its RHS entity. In particular, we sought to explore the effects of the 
addition of a carbonyl oxygen on the 6-position of 1’s RHS ring (compound 2), the effects 
of removing the N-methyl group from 2 (compound 3), and the effects of moving the methyl 
substituent over one position to the 2-position on the ring (compound 4). Additionally, in the 
same iteration, we sought to determine how the addition of another nitrogen atom to the ring 
at the 3-position to convert it into a pyrimidine (compound 5) would affect the 
pharmacological profile. As shown in Figure 2, the presence of a carbonyl oxygen 
(compounds 2–4), which may serve as potential point for hydrogen bonding with a polar 
receptor residue, appeared to substantially increase the activity of those compounds over the 
baseline 1. Further, this initial mini-series of analogues also suggested that conversion of the 
tetrahydropyridine ring into its pyrimidine version represented another favorable change that 
provided an additional boost in compound 5’s activity (GS-cAMP EC50 = 133 nM, EMAX = 
96%; β-arrestin2 EC50 > 10,000 nM) compared to compound 3 (GS-cAMP EC50 = 176 nM, 
EMAX = 81%; β-arrestin2 no activity) (Table S1).
On the basis of these results, we designed our next series of analogue ligands starting from 
compound 5 (Figure 3). The compounds in this series were created using a similar synthetic 
strategy (Scheme 1, second iteration). In this series, we sought to explore the effects of 
removing the 6-position carbonyl group on the RHS ring but retaining the core pyrimidine 
heterocycle (compound 6), adding a amine substituent between the pyrimidinyl nitrogens at 
position 2 (compound 7), adding a second nitrogen substituent at the 6-position, which was 
the original position of the carbonyl group (compound 8), and the effect of changing both of 
the nitrogen substituents back into carbonyl groups to give an unsubstituted pyrimidine 
dione moiety (compound 9). On the basis of this series of compounds, we observed a clear 
trend suggesting that the carbonyl oxygens (compounds 5 and 9) were preferred over 
nitrogen substituents (compounds 6–8) and that the pyrimidine dione moiety (9) resulted in 
significantly greater activity in both the GS-cAMP and β-arrestin2 pathways (GS-cAMP 
EC50 = 9.0 nM, EMAX = 78%; β-arrestin2 EC50 = 2089 nM, EMAX = 37%) compared to the 
diaminopyrimidine analogue (8) (GS-cAMP EC50 > 10,000 nM; β-arrestin2 no activity) 
(Table S2).
In continuing our optimization of the RHS moiety, we next synthesized a targeted series of 
compounds based on the structure of 9 (Figure 4). These particular compounds were 
prepared using similar methods as outlined previously (Scheme 1, third iteration). Starting 
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from 9, we first sought to explore the effect of adding two methyl substituents to the 1- and 
5-positions of the pyrimidine dione ring (compound 10), which would be predicted to 
increase the steric hindrance preventing RHS ring rotation about the bond axis. We also then 
explored the effect of removing the 4-position carbonyl oxygen from 10 (compound 11). 
Finally, we constructed analogues featuring variations to the positions of the same structural 
elements present in 11’s RHS, giving rise to compounds 12 and 13 as structural isomers. Not 
surprisingly based on the trends outlined by Davoren et al.,69 the dimethyl substituents of 10 
resulted in a dramatic increase in its potency and efficacy in both the GS-cAMP and β-
arrestin2 pathways relative to the unsubstituted 9 (Figure 4). Compound 10, which was very 
recently disclosed by Wang et al., was reported to have an EC50 = 0.3 nM and EMAX = 
107% in the GloSensor-measured GS-cAMP pathway and an EC50 = 35 nM and EMAX = 
86% in recruiting β-arrestin2 as determined in a Tango assay.73 In our assays, however, we 
observed similar potency and efficacy in the GS-cAMP pathway but slightly increased 
potency in recruiting β-arrestin2 (GS-cAMP EC50 = 0.02 nM, EMAX = 102%; β-arrestin2 
EC50 = 3.1 nM, EMAX = 85%), as well as a slight β-arrestin2 bias (bias factor = 1.8 for β-
arrestin2). It is possible that these differences might stem from the divergent assay 
mechanisms used to quantify β-arrestin2 recruitment in these two studies; the Tango assay 
involves a signal amplification mechanism, while the BRET assay does not. In comparison 
to compound 10, the in vitro profiles of compounds 11–13 suggest that neither removing a 
carbonyl oxygen group (compound 11) nor rearranging the nitrogen atoms within the 
heterocyclic ring and altering the locations of the carbonyl oxygen entities (compounds 12 
and 13) are well-tolerated for maintaining potent, balanced activity at D1R (compound 11 
GS-cAMP EC50 = 1.8 nM, EMAX = 88%, β-arrestin2 EC50 = 151 nM, EMAX = 19%; 
compound 12 GS-cAMP EC50 = 1.1 nM, EMAX = 92%, β-arrestin2 EC50 = 196 nM, EMAX 
= 63%; compound 13 GS-cAMP EC50 = 205 nM, EMAX = 82%, β-arrestin2 no activity) 
(Table S3).
Modifications of the Pyrimidine Dione RHS.
Given the exquisite potency and efficacy that we observed with compound 10 in both the 
GS-cAMP and β-arrestin2 assays, we sought to determine whether targeted alterations to 
readily modifiable portions of the pyrimidine dione RHS could result in an improved 
compound or a compound with a unique pharmacological profile.
In the first series of modifications, we sought to explore the effects of N-alkylation at the 3-
position of the RHS ring (Figure 5). Briefly, these analogues were synthesized by reacting 
10 with various iodinated alkyl groups in the presence of sodium hydride (Scheme S1). We 
created a simple series of analogues consisting of the methyl (compound 14), ethyl 
(compound 15), and isopropyl (compound 16) derivatives (Figure 5). On the basis of the 
previous trends we observed in our earlier series in this study (compounds 2 and 3), we 
hypothesized that N-alkylation at this position would be detrimental to the potency in the β-
arrestin2 recruitment pathway. As expected, we did observe diminishing potencies and 
efficacies in both pathways (Table S4). We also observed a very mild reversal of signaling 
bias favoring β-arrestin2, relative to dopamine, as we progressed from isopropyl down to 
methyl (bias factors for β-arrestin2 isopropyl = 4.3, ethyl = 4.6, methyl = 7.3). 
Unfortunately, given that overall potencies and efficacies also diminished significantly upon 
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alkylation, this would not likely represent a viable strategy for deriving bias from this 
scaffold.
Next, we explored the possibility of modifying the size of the substituent alkyl groups at the 
1-position of the pyrimidine dione RHS (Figure 6). A set of ligands was created starting with 
a series of commercially available ureas and alkylated 2-cyanoesters (Scheme S2). We 
explored the effect of changing the 1-position methyl group into ethyl (compound 17), 
cyclopropyl (compound 18), methylcyclopropyl (compound 19), cyclobutyl (compound 20), 
n-propyl (compound 21), and n-butyl (compound 22) groups. The trends in this series of 
compounds suggest a limit in the allowed bulk of the substituent in this location before 
general ligand activity is compromised. The methyl-containing compound 10 retained the 
highest potency and efficacy in both signaling pathways (GS-cAMP EC50 = 0.02 nM, EMAX 
= 102%; β-arrestin2 EC50 = 3.1 nM, EMAX = 85%), while ethyl (compound 17) (GS-cAMP 
EC50 = 0.08 nM, EMAX = 95%; β-arrestin2 EC50 = 13 nM, EMAX = 65%) and cyclopropyl 
(compound 18) (GS-cAMP EC50 = 0.06 nM, EMAX = 90%; β-arrestin2 EC50 = 7.4 nM, 
EMAX = 74%) modifications resulted in modest reductions in potency and efficacy in 
comparison (Table S5). Further increases in substituent bulk diminished potency even 
further, as both methylcyclopropyl (compound 19) (GS-cAMP EC50 = 0.5 nM, EMAX = 
84%; β-arrestin2 no activity) and cyclobutyl (compound 20) (GS-cAMP EC50 = 0.8 nM, 
EMAX = 82%; β-arrestin2 no activity) analogues appeared even less active. Interestingly, 
recruitment in the β-arrestin2 assay appeared to be compromised to a greater extent than G 
protein pathway activation. As such, compounds in this series trended closer toward strong 
GS bias as the bulk of the 1-position alkyl substituent increased. Interestingly, when an n-
propyl chain was introduced at this position (21), activities in the GS and β-arrestin2 
recruitment assays were somewhat improved relative to the bulkier cycloalkyl-containing 
derivatives (compounds 19 and 20). An n-butyl chain at this position (22), however, was 
likely too bulky and was not well-tolerated (Figure 6).
Finally, a small set of 5-position ethyl analogues were synthesized based on the top three 
most active compounds from the previous set of analogues that explored modifications of 
alkyl size at the 1-position (Figure 7). In particular, we focused on the effect of a slight 
increase in alkyl bulk at the 5-position in compounds that also contained methyl (compound 
23), ethyl (compound 24), and cyclopropyl (compound 25) moieties at the 1-position. These 
ligands were synthesized starting with a series of commercially available alkyl ureas and 
reacting them with ethyl 2-cyanobutanoate (Scheme S2). This series of compounds revealed 
that increasing the steric bulk at the 5-position of the pyrimidine dione RHS did not result in 
further improvement in ligand activity in either the GS activation and β-arrestin2 recruitment 
assays. In general, it appeared that additional bulk at the 1- and 5-positions of the RHS 
together were tolerated but were not favorable for improving ligand activity or in 
significantly shifting functional selectivity either direction (Table S6).
Modifications of the Middle Phenyl Ring.
After making serial modifications to key areas of the pyrimidine dione RHS and examining 
the resulting derivatives in assays for both GS activation and β-arrestin2 recruitment, it is 
clear that increasing substituent bulk at the 1-, 3-, and 5-positions of the ring are not optimal 
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changes for maintaining or improving ligand activity in either downstream pathway. 
Therefore, we decided to retain the RHS core of compound 10 and instead continue our 
exploration of other scaffold regions.
Given previous findings that the middle phenyl ring of this noncatechol scaffold is sensitive 
to dramatic alteration,25,73 we opted to pursue a more targeted modification strategy for this 
particular region of the scaffold. We sought to create analogue compounds that exploited 
previous findings in that region to determine if they also held with the pyrimidine dione 
RHS (Figure 8). All of the compound derivatives that were synthesized to explore this region 
were synthesized starting with various commercially available brominated phenols using the 
same general synthetic strategy outlined previously (Scheme S3).
First, on the basis of our previous findings suggesting that moving the methyl substituent 
over one position to the 3-position on the middle phenyl ring was detrimental to ligand 
activity,25 we synthesized compound 26 to see what effect this would have on ligand activity 
and bias compared to compound 10. As expected, we observed a large reduction in potency 
and efficacy in GS activation and complete abrogation of β-arrestin2 recruitment when 26 
was examined. Compound 27, which featured an unsubstituted middle phenyl ring, was 
synthesized to probe the importance of the biaryl interlocking ring system in this scaffold. 
The findings outlined in a recent paper by Davoren et al. suggested the importance of a 
certain degree of steric bulk in the space immediately adjacent to the bond connecting the 
middle phenyl ring and the RHS because it was believed to help lock the RHS into a fixed 
position, unable to rotate about its bond axis.69 In comparison to the interlocking ring 
system in 10, the RHS of compound 27 is expected to be significantly less obstructed and 
more able to freely rotate. While activity was modestly reduced in both pathways compared 
to compound 10, compound 27 produced a much milder loss of ligand activity in both 
pathways (GS-cAMP EC50 = 0.08 nM, EMAX = 96%; β-arrestin2 EC50 = 40 nM, EMAX = 
75%) compared to compound 26 (GS-cAMP EC50 = 33 nM, EMAX = 100%; β-arrestin2 no 
activity) (Table S7). This striking difference is interesting to note in light of the fact that, 
similar to 27, compound 26 also lacks the steric bulk on the middle phenyl ring immediately 
proximal to the RHS. Given these findings, it is likely that moving the methyl substituent to 
the 3-position not only abolishes the interlocking biaryl ring system as in 27 but may also 
introduce a steric clash with a neighboring residue within D1R, thereby further reducing 
ligand potency and activity.
Iterative SFSR of the LHS Heterocycle.
Given that the findings in previous studies suggest that the LHS moiety plays a key role in 
determining the pharmacological properties of the noncatechol ligand at D1R, we opted to 
explore this region of the scaffold with two different approaches to see if we could obtain 
some important insights from either method. First, we took an iterative approach to 
designing an LHS moiety from the ground up, while fixing the RHS and middle phenyl ring 
as they appear in compound 10 (Figure 9). Derivatives in this initial series were created by 
following the same general methods previously outlined (Scheme 2).
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We began by synthesizing compound 28, which lacked an LHS moiety, to determine if the 
RHS and middle linker together could form an active ligand on their own. In addition, we 
synthesized the methoxy analogue 29 to both slightly grow the LHS in size and to cap the 
polar oxygen in the event that the terminal hydroxyl moiety was problematic for scaffold 
binding. Finally, we synthesized the pyridine analogue (compound 30) to determine the 
relative benefit of an aromatic ring at the LHS position. Our findings from this preliminary 
series of simple LHS moieties suggested the critical importance for an LHS with sufficient 
size and aromaticity, as both the hydroxy (28) and methoxy (29) analogues were inactive 
while the unsubstituted pyridine analogue (30) was considerably more active in both the GS 
activation and β-arrestin2 recruitment assays (GS-cAMP EC50 = 8.1 nM, EMAX = 107%; β-
arrestin2 EC50 = 172 nM, EMAX = 40%) (Table S8). Compound 30 was a potent full agonist 
in stimulating GS activation and served as a partial agonist of β-arrestin2 recruitment.
On the basis of our results from the initial set of LHS derivatives, we synthesized a series of 
four additional derivatives based on compound 30 (Figure 10). These ligands, which were 
synthesized with commercially available substituted pyridines (Scheme 2), aimed to explore 
the effects of various mono- and disubstitution patterns on the LHS pyridine core. In 
particular, we initially explored the effect of a 4-methoxy substituent (compound 31), a 3-
trifluoromethyl substituent (compound 32), 3-cyano-4-methoxy substituents (compound 33), 
and 3-trifluoromethyl-4-chloro substituents (compound 34) on the LHS pyridine. 
Interestingly, similar to the unsubstituted pyridine analogue 30, the monosubstituted 
derivatives 31 and 32 displayed potent full agonism in the GS activation assay as well as 
partial agonism in the β-arrestin2 recruitment assay (compound 31 GS-cAMP EC50 = 2.0 
nM, EMAX = 108%; β-arrestin2: EC50 = 52 nM, EMAX = 27%; compound 32 GS-cAMP 
EC50 = 0.8 nM, EMAX = 118%; β-arrestin2 EC50 = 68 nM, EMAX = 30%) (Table S9). The 
disubstituted ligands 33 and 34, however, became completely GS biased, albeit with only 
relatively mild potency and partial agonism displayed in the GS activation assay (compound 
33 GS-cAMP EC50 = 23 nM, EMAX = 59%; β-arrestin2 no activity; compound 34 GS-cAMP 
EC50 = 105 nM, EMAX = 82%; β-arrestin2 no activity). On the basis of the interesting trends 
observed in this series of ligands, we sought to determine if we could combine the favorable 
elements of potency and efficacy obtained from 4-methoxy and 3-trifluoromethyl 
substituents with the enhanced GS bias observed with pyridine disubstitution on this scaffold 
to create a highly GS-biased ligand with enhanced potency. The resulting hybrid compound 
35, which featured both a 4-methoxy substituent and a 3-trifluoromethyl substituent, was in 
fact a potent GS-biased ligand. Of note, compound 35 was also characterized as a partial 
agonist in the GS activation assay (GS-cAMP EC50 = 1.8 nM, EMAX = 66%; β-arrestin2 no 
activity), while the two monosubstituted analogues 31 and 32 were both full agonists in the 
GS activation assay (Table S9). This is an interesting finding that warrants further 
investigation in medicinal chemistry, mutagenesis, and computational modeling 
experiments. Further, we believe that compounds 31, 32, and 35 together form a powerful 
set of chemical tools that can be used to further explore the structural determinants of both 
GS bias and partial agonism in D1R.
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Modifications of the Pyridofuran LHS.
The LHS pyridofuran entity, which has been consistent feature of all of the most active 
compounds synthesized from this scaffold in both past studies25,68,69 and in the current 
study (as with compound 10), represents an important element of the noncatechol scaffold 
and likely contributes to ligand pharmacology through its electronic and spatial properties. 
Therefore, the second approach we took to explore the critical elements of the LHS region of 
the scaffold was to make very slight modifications to the pyridofuran entity (Figure 11). 
Synthesis of these derivatives followed the same general procedures previously discussed 
(Scheme S4).
Briefly, we synthesized two analogues exploring the effects of methylation at various ring 
positions, including the 2-position of the pyridofuran ring (compound 36) and at the 1-
position, which required switching the pyridofuran LHS into a pyrrolopyridine (compound 
37). In addition, the effect of removing the 1-position oxygen altogether was explored 
(compound 38), as was conversion of the 1-position oxygen to a sulfur giving a 
thienopyridinyl (compound 39). Finally, on the basis of results from our previous study 
demonstrating that a thieno[2,3-c]pyridine moiety on the LHS could dramatically increase 
the scaffold’s ability to stimulate β-arrestin2 recruitment,25 we introduced this LHS moiety 
into this particular set of derivatives (compound 40). Characterization of this series of 
ligands in GS activation and β-arrestin2 recruitment assays revealed some surprising SFSR 
trends and yielded several novel compounds with interesting functional selectivity profiles 
(Figure 11).
First, we observed that simple methylation of the 2-position of the pyridofuran moiety (36) 
converted the potent, balanced agonist 10 into a less potent partial agonist with complete GS-
bias (GS-cAMP EC50 = 4.5 nM, EMAX = 69%; β-arrestin2 no activity). The 1-methyl 
pyrrolopyridine derivative 37 displayed similar GS-biased partial agonism, albeit with 
improved potency (GS-cAMP EC50 = 0.8 nM, EMAX = 74%; β-arrestin2 no activity). 
Compound 38 was also GS-biased (GS-cAMP EC50 = 0.4 nM, EMAX = 115%; β-arrestin2 
EC50 > 10 000 nM), though it did retain slightly more activity in β-arrestin2 recruitment 
compared to 37. Compound 39, which featured a thieno[3,2-c]pyridine moiety on the LHS, 
displayed diminished activity in both the GS activation and β-arrestin2 recruitment assays 
(GS-cAMP EC50 = 7.0 nM, EMAX = 104%; β-arrestin2 EC50 = 13 nM, EMAX = 30%) (Table 
S10). These two compounds underscore the importance of the furan oxygen in the bicyclic 
LHS for maintaining potent balanced agonism with this scaffold, as neither carbon nor sulfur 
substitutions were as well-tolerated.
Finally, when the thieno[2,3-c]pyridine moiety was introduced on the scaffold LHS, the 
activity of the resulting compound 40 in both the GS activation and β-arrestin2 recruitment 
assays remained roughly similar (GS-cAMP EC50 = 0.02 nM, EMAX = 107%; β-arrestin2 
EC50 = 3.5 nM, EMAX = 65%) to that of compound 10 (Table S10). Further work remains to 
continue understanding the drivers of β-arrestin2 recruitment at D1R and synthesizing 
compounds with improved β-arrestin2 bias. Nevertheless, the interesting SFSR trends of the 
LHS suggest that this region of the scaffold is critical for enabling potent, β-arrestin2 
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recruitment and may potentially be leveraged to design the first β-arrestin2-biased D1R 
agonist.
Taken together, an iterative design strategy employed at both ends of an interesting 
noncatechol scaffold yielded several novel compounds with highly diverse functional 
selectivity profiles and bias factors (Figure 12). In addition, compared to previous SFSR 
strategies in the field, ligand design from this “ground up” approach enabled the 
development of better insights and a clearer understanding of precisely which structural 
components were critical for the scaffold’s potency, efficacy, and signaling bias.
Binding Affinity and Selectivity.
Our ground-up exploration and synthesis of novel noncatechol compounds yielded several 
interesting new candidates that we subsequently tested in validated radioligand binding 
affinity assays to assess target selectivity.74 In particular, we selected six ligands from our 
study that possessed unique structural elements and in vitro functional selectivity profiles 
and tested them for their affinity across a broad panel of over 30 potential off-target proteins, 
including Class A aminergic GPCRs, transporters, and ion channels. Compounds were first 
screened in primary radioligand binding assays to determine if they reached a certain affinity 
threshold (measured as % inhibition) for any target on the panel. Compounds with a mean 
inhibition greater than 50% at 10 μM across four independent determinations were 
considered to have met the affinity threshold and were subsequently examined in secondary 
radioligand binding assays for Ki determination at each receptor that met the minimum 
threshold.
We chose to examine the relatively balanced ligands 10 and 40, the highly GS-biased ligands 
35, 36, and 37, and the slightly β-arrestin2-biased ligand 18. The results from these 
experiments clearly indicate that regardless of potency, efficacy, or functional selectivity, 
derivatives of this noncatechol scaffold retain high selectivity for the D1-like dopamine 
receptors, D1R and D5R (Table 1).
Mouse Pharmacokinetic Studies.
Previous studies of this scaffold suggest that it possesses excellent pharmacokinetic 
properties and blood–brain barrier (BBB) penetrance, likely owing to its small molecular 
weight, relative hydrophobicity, and lack of a catechol group.25,68 In this study, we 
discovered a series of novel compounds with chemical entities that differ significantly from 
those described in previous studies. In particular, the pyrimidine dione moiety on the RHS is 
a new addition that distinguishes these series of compounds from those in previous studies 
that examined pharmacokinetics and BBB penetration. Further, this RHS structure is 
relatively more polar, and from a chemical perspective, appears to be highly capable of 
forming hydrogen bonding interactions. Therefore, we were not sure how well these 
structural modifications would be tolerated when these ligands were tested in vivo.
To adequately assess the in vivo pharmacokinetic properties of a representative set of 
ligands, we selected compounds 10 and 35 to be administered to mice in triplicate. Each 
compound was administered to mice through an intraperitoneal (i.p.) injection at a dose of 
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approximately 50 mg/kg. The drug concentrations were monitored in the brain and plasma at 
three time points, 0.5, 1.5, and 4.0 h after injection. This study revealed that, despite 
potential concerns that the chemical structures of this series may impede BBB penetrance or 
lower plasma exposure, the ligands all displayed excellent pharmacokinetic properties and 
BBB penetrance (Figure 13). For example, compounds 10 and 35 both reached peak 
concentrations of nearly 100 μM in the brain and plasma after administration at 50 mg/kg. 
These high concentration levels persisted well up to even 4 hours after administration. 
Further, despite administration at a relatively high dose, the compounds appeared well-
tolerated and none of them appeared to induce any adverse clinical signs in the animals.
Together, these two ligands, which each display unique differences in their potencies, 
efficacies, and functional selectivity profiles, both possess excellent pharmacokinetic 
properties and BBB penetrance. These features indicate that these ligands may be valuable 
tools for the scientific community to further explore the roles of biased and balanced 
signaling at D1R.
Behavioral Studies in Mice.
The highly selective activity of this class of noncatechol agonists for the D1-like receptors 
D1R and D5R, as well as the favorable pharmacokinetic properties and high BBB 
penetrance, encouraged us to examine how a subset of these ligands with diverse functional 
selectivity profiles could impact various behavioral and physiological outcomes in animal 
studies. One particularly compelling pathophysiological domain for investigating the role of 
D1R agonism and functional selectivity is in the treatment of PD and LID.
In a previous study by Gray et al., a GS-biased noncatechol ligand was administered in an 
acute rodent model of PD.68 Interestingly, compared to dopamine, the ligand was found to 
produce a more sustained dopaminergic response in the animals. This was believed to be due 
to the inability of the GS-biased ligands to recruit β-arrestin2, thereby attenuating any β-
arrestin2-mediated desensitization and tachyphylaxis which may occur after repeated 
dosing. Separate studies of D1R signaling in rodent PD models have suggested that the GS-
mediated pathway may actually be responsible for the development of LID after long-term 
treatment with L-DOPA.75 At the same time, genetic models have suggested that β-arrestin2-
mediated signaling may attenuate LID while still remedying locomotor deficits.20,21,75 
Despite the varying hypotheses of which downstream signaling pathway may be more 
important to target, the complex pathophysiology underlying these models and disease states 
make them fascinating systems in which to apply our ligands to study GPCR functional 
selectivity.
For these reasons, we opted to explore how our ligands might impact animal behaviors in 
animal models of PD. For our studies, we used 6-hydroxydopamine (6-OHDA)-lesioned 
mice as an animal model of PD. Unilateral injection of 6-OHDA into medial forebrain 
bundle in rodents results in supersensitivity of central dopamine receptors, a state 
conceptualized as similar to PD.76 Similarly, unilaterally 6-OHDA-lesioned rodents treated 
with L-DOPA develop “dyskinesias” consisting of contralateral turning of the neck and 
jerking of contralateral forelimbs.77,78 For these reasons, 6-OHDA-lesioned mice represent a 
relevant model of PD that is widely used in the field of neuroscience for studying PD 
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pathophysiology. In these studies, we chose to focus our experiments on compound 10. We 
selected compound 10 because it was a balanced agonist with high potency in both signaling 
assays and displayed highly favorable pharmacokinetic properties and BBB penetrance, with 
minimal decline in concentrations achieved in the brain or plasma even up to 4 hours after 
administration.
Compound 10 was administered to 6-OHDA-lesioned mice as a 5 mg/kg intraperitoneal 
injection (i.p.). SKF81297, a known D1/D5-selective full agonist, was also administered at 5 
mg/kg i.p. in a cohort of mice as a positive control, while vehicle was administered as a 
negative control. The motor activities of the mice were subsequently monitored using an 
automated tracking system that included overhead recording cameras and sensor beams that 
detect movement within the arena. The distances traveled by the mice and the number of 
contralateral rotations they performed were tracked, recorded, and quantified. Both of these 
motor behaviors are recognized as lines of evidence supportive of central dopaminergic 
stimulation in 6-OHDA model of PD.79–82
We found that injection of compound 10 into 6-OHDA-lesioned mice produced statistically 
significant increases in forward locomotion at each measured time interval (Figure 14A) and 
in the total distance traveled during the observation period (Figure 14B), compared to the 
vehicle control. Similar effects were observed in mice that were administered SKF81297. 
We also observed significant increases in the number of contralateral rotations that the mice 
performed when they were injected with either compound 10 or SKF81297 (Figure 14C and 
D).
Interestingly, in both of these experiments, we noted a gradual decline in the behavioral 
efficacy of the SKF81297 control compound over the 90 min study interval, particularly 
starting around the 50 min mark, while this effect was not observed with compound 10. As 
such, SKF81297-treated mice no longer displayed significantly increased forward 
locomotion compared to vehicle after 1 h, while compound 10-treated mice did (Figure 
14B). While it is possible that this may be related to the pharmacokinetic differences 
between the ligands, such as a longer half-life or better BBB penetration, future investigation 
should be performed to better determine the factors that may be contributing to this 
phenomenon. Regardless, these studies suggest that compound 10 is a potent dopaminergic 
agonist that demonstrates robust in vivo activity, comparable to other known D1 agonists, 
and is suitable for in vivo studies of dopamine signaling and transmission.
CONCLUSION
We conducted a novel exploratory study that takes a significantly different approach to 
ligand discovery from both our previous systematic SFSR campaign and other studies 
reporting non-catechol analogues of D1R. Here, we utilize the lessons and trends learned 
from previous studies to design novel ligands “from the ground up”. From this approach, we 
obtained a better understanding of precisely which structural components are critical for the 
scaffold’s potency, efficacy, and signaling bias. In addition, we report the discovery of 
several new scaffold derivatives with bias signaling properties and robust in vivo activity. In 
particular, compound 10 is a balanced full agonist at D1R with picomolar potency, while 
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compounds 35, 36, and 37 are completely GS-biased partial agonists with low nanopolar 
potency. We also report the discovery of compound 40, an analogue of 10 with low 
nanomolar potency and balanced activity in stimulating the β-arrestin2 signaling pathway.
Despite the exquisite potency of these compounds at D1R, these ligands also remained 
highly selective for the D1-like receptors, D1R and D5R, when tested across a broad panel of 
potential off-targets, including Class A aminergic GPCRs, ion channels, and transporters. 
Importantly, compounds 10 and 35 were also demonstrated to have good BBB penetrance 
and maintain stable levels in the brain and plasma for at least 4 hours after administration. 
Upon intraperitoneal administration in a 6-OHDA mouse model of PD, compound 10 
demonstrated antiparkinsonian and pro-dyskinetic potential through restoration of 
locomotion and potentiation of behaviors indicative of dyskinesia. This is the first in vivo 
characterization of a potent, unbiased noncatechol D1R agonist. Taken together, the results 
from this study suggest that the ligands developed herein have strong potential to serve as 
chemical tools for future work investigating the effects of biased signaling at D1R. Finally, 
we believe that this study may also serve as a valuable template for an iterative approach to 
functionally selective GPCR ligand discovery, carrying particular relevance to exploring the 
structural determinants of a ligand that are critical for biased signaling.
METHODS
Chemistry General Procedures.
Each of the reagents in this study were of commercial grade and were used without 
additional purification. Dry solvents were purchased from Sigma-Aldrich and were 
anhydrous. Procedures necessitating microwave heating involved the use of a Discover SP 
microwave system with an Explorer 12 Hybrid Autosampler by CEM (Buckingham, UK). 
Reactions performed via microwave heating were conducted at 125 °C for 25 min using 250 
W and a pressure less than 300 psi. Analytical thin-layer chromatography (TLC) was carried 
out using EMD Millipore 210–270 μm 60-F254 silica gel plates. TLC plate visualization 
was done using 254 μm UV light. Flash column chromatography was implemented with a 
Teledyne (Thousand Oaks, CA) ISCO CombiFlash Rf+ system. This system was equipped 
with normal phase RediSep Rf silica columns, a UV detector, and a fraction collector 
apparatus. A preparative high-performance liquid chromatography (HPLC) system was used 
to purify all final compounds. Preparative HPLC was performed using an Agilent Prep 1200 
series with a Phenomenex Luna 750 mm × 30 mm, 5 μm, C18 column, with column injection 
proceeding at room temperature. HPLC solvent flow rate was set to 40 mL/min while the 
UV detector was set to 254 nm. A linear gradient was set for the purification program and 
consisted of 10% (or 50%) MeOH (A) in H20) (with 0.1% TFA) (B) to 100% MeOH (A). 
HPLC was used to establish the purity of each target compound. All biologically evaluated 
compounds had >95% purity after purification via the HPLC methods described. A liquid 
chromatography–mass spectrometer (LC-MS) was used to characterize all compounds. 
Liquid chromatography–high-resolution mass spectrometry (LC-HRMS) was used to further 
assess key compounds, as follows. An Agilent 1200 series system, fully equipped with a 
DAD detector, was used to acquire HPLC spectra for all compounds. This system contained 
a 2.1 mm × 150 mm Zorbax 300SB-C18 5 μm column and the flow rate was set to 0.4 mL/
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min. The solvents used in the separation gradient program were as follows: solvent A 
included water containing 0.1% formic acid and solvent B included acetonitrile containing 
0.1% formic acid. The separation gradient program included 1% B from 0 to 1 min, 
followed by 1–99% B from 1 to 4 min, and finally 99% B from 4 to 8 min. The resulting 
spectra were used in reporting the HPLC retention times for the compounds below. HRMS 
data was also obtained for key compounds below. To obtain HRMS data, samples were 
ionized by electrospray ionization (ESI) in positive mode. HRMS analysis was conducted 
using a G1969A high-resolution API-TOF mass spectrometer by Agilent Technologies. To 
this spectrometer was attached the 1200 HPLC system described previously. Nuclear 
magnetic resonance (NMR) spectroscopy was also implemented for the characterization of 
all compounds. NMR spectra were acquired on a Bruker (Billerica, MA) DRX-600 
spectrometer. The chemical shifts reported below are given in parts per million (ppm, δ) and 
are relative to residual solvent peaks (CD3OD, 1H 3.31 ppm; CDCl3, 1H 7.26 ppm). Data 
below reported from the 1H NMR spectra are given as chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, app = apparent), 
coupling constant, and integration.
4-(3-Methyl-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenoxy)furo[3,2-
c]pyridine (1).—To an oven-dried microwavable tube was added a stir bar, 
tetrakis(triphenylphosphine)palladium(0) (26 mg, 0.023 mmol), potassium carbonate (44 
mg, 0.32 mmol), 4-bromo-1-methyl-1,2,3,6-tetrahydropyridine (27 mg, 0.15 mmol), and the 
known intermediate 4-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)furo[3,2-c]pyridine25,68,69 (60 mg, 0.17 mmol) in dioxane (1 mL) and water (0.2 
mL). Microwave irradiation was then applied to the mixture at 125 °C for 25 min, as 
described in the General Chemistry Procedures section. The resulting mixture was 
subsequently filtered through Celite; the filter was washed with several times with ethyl 
acetate, and the organic filtrate diluted with water and extracted three times with ethyl 
acetate. Brine and saturated aqueous NaHCO3 were then used to wash the combined organic 
layers. The organic layers were then dried over anhydrous MgSO4 and concentrated in 
vacuo. The resulting residue was taken up in 2 mL of methanol and purified by HPLC using 
the conditions described previously. This procedure yielded compound 1 as a clear oil (5.6 
mg, 11%). 1H NMR (500 MHz, methanol-d4): δ 7.98 (d, J = 5.9 Hz, 1H), 7.90 (d, J = 2.2 
Hz, 1H), 7.41 (dd, J = 5.9, 1.0 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 
7.05 (dd, J = 8.3, 2.5 Hz, 1H), 6.84 (p, J = 1.1 Hz, 1H), 5.73–5.68 (m, 1H), 4.08 (d, J = 16.5 
Hz, 1H), 3.84 (dd, J = 16.7, 3.1 Hz, 1H), 3.72 (dd, J = 12.3, 5.9 Hz, 1H), 3.45 (td, J = 11.6, 
4.9 Hz, 1H), 3.06 (s, 3H), 2.97 (d, J = 9.1 Hz, 1H), 2.64 (d, J = 18.5 Hz, 1H), 2.37 (s, 3H). 
MS (ESI): m/z 321.2 [M + 1]+.
4-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-1-methylpyridin-2(1H)-one 
(2).—Compound 2 was prepared as a clear oil using the same procedure outlined above for 
the preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 4-bromo-1-
methylpyridin-2(1H)-one, yield = 25%. 1H NMR (600 MHz, methanol-d4): δ 8.02 (s, 1H), 
7.93 (s, 1H), 7.75 (s, 1H), 7.44 (s, 1H), 7.34 (s, 1H), 7.20 (s, 1H), 7.14 (s, 1H), 6.83 (s, 1H), 
6.55 (s, 1H), 6.49 (s, 1H), 3.36–3.29 (m, 3H), 2.36 (s, 3H). MS (ESI): m/z 333.1 [M + 1]+.
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Compound 2 was prepared as a clear oil using the same procedure as was used for the 
preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaboro-lan-2-yl)phenoxy)furo[3,2-c]pyridine and 4-
bromopyridin-2(1H)-one, yield = 64%. 1H NMR (600 MHz, methanol-d4): δ 7.99 (s, 1H), 
7.92 (s, 1H), 7.71 (s, 1H), 7.44 (s, 1H), 7.35 (s, 1H), 7.19 (s, 1H), 7.16 (s, 1H), 6.86 (s, 1H), 
6.52 (s, 1H), 6.51 (s, 1H), 2.37 (s, 3H). MS (ESI): m/z 319.1 [M + 1]+.
4-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-6-methylpyridin-2(1H)-one 
(4).—Compound 2 was prepared as a clear oil using the same procedure as was used for the 
preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 4-bromo-6-
methylpyridin-2(1H)-one, yield = 51%. 1H NMR (600 MHz, methanol-d4): δ 8.03 (d, J = 
5.9 Hz, 1H), 7.94 (d, J = 2.3 Hz, 1H), 7.47 (d, J = 6.0 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.23 
(s, 1H), 7.17 (d, J = 8.2 Hz, 1H), 6.86 (s, 1H), 6.61 (s, 1H), 6.56 (s, 1H), 2.48 (s, 3H), 2.38 
(s, 3H). MS (ESI): m/z 333.1 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)pyrimidin-4(3H)-one (5).—
Compound 2 was prepared as a clear oil using the same procedure as was used for the 
preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 6-
bromopyrimidin-4(3H)-one, yield = 5%. 1H NMR (600 MHz, methanol-d4): δ 8.32 (s, 1H), 
8.00 (d, J = 5.9 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.41 (d, J = 5.9 
Hz, 1H), 7.18 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 8.4, 2.5 Hz, 1H), 6.91 (d, J = 2.2 Hz, 1H), 
6.56 (s, 1H), 2.46 (s, 3H). MS (ESI): m/z 320.1 [M + 1]+.
4-(3-Methyl-4-(5-methylpyrimidin-4-yl)phenoxy)furo[3,2-c]-pyridine (6).—
Compound 2 was prepared as a clear oil using the same procedure as was used for the 
preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaboroan-2-yl)phenoxy)furo[3,2-c]pyridine and 4-bromo-5-
methylpyrimidine, yield = 78%. 1H NMR (500 MHz, methanol-d4): δ 9.16 (s, 1H), 8.07 (d, J 
= 6.0 Hz, 1H), 7.96–7.92 (m, 1H), 7.50–7.47 (m, 2H), 7.34 (d, J = 8.3 Hz, 1H), 7.28 (d, J = 
2.3 Hz, 1H), 7.23–7.20 (m, 1H), 6.82 (dt, J = 2.3, 1.1 Hz, 1H), 2.27 (s, 3H), 2.17 (s, 3H). MS 
(ESI): m/z 318.1 [M + 1]+.
4-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-methylpyrimidin-2-amine 
(7).—Compound 2 was prepared as a clear oil using the same procedure as was used for the 
preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 4-bromo-5-
methylpyrimidin-2-amine, yield = 99%. 1H NMR (500 MHz, methanol-d4): δ 8.51 (s, 1H), 
8.03 (d, J = 5.8 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H), 7.47–7.42 (m, 1H), 7.40 (d, J = 8.4 Hz, 
1H), 7.28 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 8.4, 2.4 Hz, 1H), 6.93 (dd, J = 2.2, 1.0 Hz, 1H), 
2.28 (s, 3H), 2.12 (s, 3H). MS (ESI): m/z 333.1 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)pyrimidine-2,4-diamine (8).—
Compound 2 was prepared as a clear oil using the same procedure as was used for the 
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preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 6-
bromopyrimidine-2,4-diamine, yield = 19%. 1H NMR (500 MHz, methanol-d4): δ 7.99 (dd, 
J = 5.9, 1.5 Hz, 1H), 7.93 (d, J = 2.5 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.43 (dd, J = 5.9, 1.7 
Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.18–
6.14 (m, 1H), 2.43 (s, 3H). MS (ESI): m/z 334.1 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)pyrimidine-2,4(1H,3H)-dione 
(9).—Compound 2 was prepared as a clear oil using the same procedure as was used for the 
preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 6-
bromopyrimidine-2,4(1H,3H)-dione, yield = 26%. 1H NMR (600 MHz, methanol-d4): δ 
7.97 (d, J = 11.0 Hz, 1H), 7.91 (d, J = 14.9 Hz, 1H), 7.43 (d, J = 17.0 Hz, 2H), 7.19 (d, J = 
13.3 Hz, 1H), 7.15 (s, 1H), 6.95 (d, J = 14.2 Hz, 1H), 5.61 (d, J = 14.6 Hz, 1H), 2.42 (s, 3H). 
MS (ESI): m/z 336.1 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (10).—A 4.4 M solution of NaOMe (11.9 
mmol) in methanol was added to a solution of 1-methylurea (0.83 g, 10.9 mmol) and ethyl 
2-cyanopropanoate (9.96 mmol) in methanol (7.5 mL). The reaction was then heated at 
reflux for 18 h, and then cooled to room temperature. The solvent was then removed under 
vacuum, and the residue was taken up in acetonitrile and repeatedly evaporated. The residue 
was then partitioned in 1:1 acetonitrile: H2O and 6 M HCl was added until the pH was 
measured to be 2. At this point, the mixture was stirred for 1 h to allow precipitate 
formation. The precipitate was then collected, filtered, and washed with diethyl ether to 
generate the intermediate 6-amino-1,5-dimethylpyrimidine-2,4-(1H,3H)-dione in good 
yields and was used in subsequent reactions without further purification. 6-Amino-1,5-
dimethylpyrimidine-2,4-(1H,3H)-dione (6.7 mmol) was then reacted with NaNO2 (10.2 
mmol) and CuBr2 (13.4 mmol) in solution of acetonitrile (7 mL) and H2O (7 mL) at room 
temperature for 66 h. After it was stirred for 66 h, approximately 20 mL of 1 N H2SO4 and 
10 mL of ethyl acetate were added to enable precipitation to occur. The resulting precipitate 
was then collected by filtration and washed with ethyl acetate and H2O before being dried 
under vacuum. This yielded the intermediate 6-bromo-1,5-dimethylpyrimidine-2,4(1H,3H)-
dione (10i) in excellent yield and the material was used in subsequent reactions without 
further purification. Compound 10 was prepared as a clear oil using the same procedure as 
was used for the preparation of compound 1 starting with the intermediate 4-(3-methyl-4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 6-bromo-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (10i), yield = 31%. 1H NMR (600 MHz, methanol-
d4): δ 8.01 (d, J = 5.8 Hz, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.43 (d, J = 5.9 Hz, 1H), 7.30 (d, J = 
8.4 Hz, 2H), 7.23 (d, J = 8.5 Hz, 1H), 6.96 (s, 1H), 3.08 (h, J = 2.5, 1.7 Hz, 3H), 2.24 (s, 
3H), 1.67 (h, J = 2.7, 2.0 Hz, 3H). HPLC 99% pure, tR = 4.745 min. HRMS: m/z [M + H]+ 
calculated for C20H18N3O4+ 364.1292, found 364.1299.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-1,5-dimethylpyrimidin-2(1H)-
one (11).—Compound 2 was prepared as a clear oil using the same procedure as was used 
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for the preparation of compound 1 starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 6-bromo-1,5-
dimethylpyrimidin-2(1H)-one, yield = 56%. 1H NMR (600 MHz, methanol-d4): δ 8.72 (s, 
1H), 8.02 (d, J = 5.9 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.47–7.44 (m, 1H), 7.39 (s, 1H), 
7.37–7.31 (m, 2H), 7.03 (d, J = 2.1 Hz, 1H), 3.45 (s, 3H), 2.24 (s, 3H), 1.96 (s, 3H). MS 
(ESI): m/z 348.1 [M + 1]+.
5-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-4-methylpyridazin-3(2H)-one 
(12).—To an oven-dried flask was added 4,5-dimethylpyridazin-3-ol (4.2 g, 25 mmol), 3,4-
dihydro-2H-pyran (16.8 g, 200 mmol), p-toluenesulfonic acid monohydrate (0.95 g, 5 
mmol), and tetrahydrofuran (200 mL). The solution was stirred overnight to give 4,5-
dichloro-2-(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one (5.7 g, 22.88 mmol), which was 
subsequently reacted with methylboronic acid (1.37 g, 22.88) in the presence of cesium 
carbonate (22.36 g, 68.64 mmol), [1,1′-bis(diphenylphosphino)ferrocene]-
dichloropalladium(II) (0.83 g, 1.14 mmol), dioxane (40 mL), and water (4 mL) at 110 °C for 
2 h. Chromatography and mass spectrometry revealed that this reaction resulted in 
production of both of the structural isomers, 5-chloro-4-methyl-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2H)-one (12i) and 4-chloro-5-methyl-2-(tetrahydro-2H-pyran-2-
yl)pyridazin-3(2H)-one (13i). Compound 12 was prepared as a light yellow residue using a 
modified Suzuki coupling procedure starting with the intermediate 4-(3-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-c]pyridine and 5-chloro-4-methyl-2-
(tetrahydro-2H-pyran-2-yl)pyridazin-3(2H)-one (12i). In this modified procedure, after the 
Suzuki coupling reaction was performed as described for the preparation of compound 1, the 
resulting reaction mixture was filtered over Celite, slowly acidified by the dropwise addition 
of 4.0 M HCl in dioxanes, and stirred overnight to allow full deprotection prior to HPLC 
purification. This method afforded the desired compound 12, yield = 34%. 1H NMR (600 
MHz, methanol-d4): δ 7.98 (d, J = 23.5 Hz, 1H), 7.91 (d, J = 13.6 Hz, 1H), 7.79–7.73 (m, 
1H), 7.65 (s, 1H), 7.42 (s, 1H), 7.24 (s, 1H), 7.17 (s, 1H), 6.89 (s, 1H), 2.19 (s, 3H), 2.02 (s, 
3H). MS (ESI): m/z 334.1 [M + 1]+.
4-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-methylpyridazin-3(2H)-one 
(13).—Compound 13 was prepared as a light yellow residue using the same modified 
procedure as was used for the preparation of compound 12 above starting with the 
intermediate 4-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo-[3,2-
c]pyridine and 4-chloro-5-methyl-2-(tetrahydro-2H-pyran-2-yl)-pyridazin-3(2H)-one (13i), 
yield = 24%. 1H NMR (600 MHz, methanol-d4): δ 7.99 (d, J = 5.9 Hz, 1H), 7.96 (s, 1H), 
7.88 (d, J = 2.3 Hz, 1H), 7.39 (d, J = 5.9 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 7.17 (d, J = 8.2 
Hz, 1H), 7.14–7.10 (m, 1H), 6.87 (s, 1H), 2.16 (s, 3H), 2.10 (s, 3H). MS (ESI): m/z 334.1 
[M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-1,3,5-
trimethylpyrimidine-2,4(1H,3H)-dione (14).—To an oven-dried flask was added a stir 
bar, compound 10 (40 mg, 0.11 mmol), lithium bromide (11.5 mg, 0.13 mmol), sodium 
bis(trimethylsilyl)amide (24.3 mg, 0.13 mmol), and anhydrous N,N-dimethylformamide (1.0 
mL). The reaction was allowed to stir at room temperature under N2 for 30 min before the 
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dropwise addition of methyl iodide (0.143 mmol). The reaction was then stirred overnight, 
then quenched with H2O, and neutralized to pH 7 with 1 M HCl. The solution was then 
extracted three times with ethyl acetate, dried over anhydrous sodium sulfate, concentrated 
in vacuo, and purified by HPLC to give compound 14 as a tan oil, yield = 46%. 1H NMR 
(600 MHz, methanol-d4): δ 8.02 (s, 1H), 7.94 (s, 1H), 7.44 (s, 1H), 7.30 (s, 2H), 7.24 (s, 
1H), 6.96 (s, 1H), 3.43 (s, 3H), 3.14 (s, 3H), 2.24 (s, 3H), 1.71 (s, 3H). MS (ESI): m/z 378.1 
[M + 1]+.
3-Ethyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (15).—Compound 15 was prepared as a tan oil 
using the same procedure as was used for the preparation of compound 14 starting with 
compound 10 and instead using ethyl iodide, yield = 56%. 1H NMR (600 MHz, methanol-
d4): δ 8.02 (s, 1H), 7.94 (s, 1H), 7.43 (s, 1H), 7.34–7.26 (m, 2H), 7.24 (s, 1H), 6.96 (s, 1H), 
4.11 (s, 2H), 3.13 (s, 3H), 2.24 (s, 3H), 1.70 (s, 3H), 1.29 (s, 3H). MS (ESI): m/z 392.2 [M 
+ 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-3-isopropyl-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (16).—Compound 16 was prepared as a tan oil 
using the same procedure as was used for the preparation of compound 14 starting with 
compound 10 and instead using isopropyl iodide, yield = 23%. 1H NMR (600 MHz, 
methanol-d4): δ 8.01 (d, J = 7.7 Hz, 1H), 7.92 (s, 1H), 7.42 (s, 1H), 7.27 (d, J = 9.0 Hz, 2H), 
7.21 (s, 1H), 6.95 (s, 1H), 3.09 (s, 3H), 2.23 (s, 3H), 1.67 (s, 3H), 1.57 (d, J = 6.9 Hz, 1H), 
1.53 (t, 6H). MS (ESI): m/z 406.2 [M + 1]+.
1-Ethyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-
methylpyrimidine-2,4(1H,3H)-dione (17).—Compound 17 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-ethylurea and ethyl 2-cyanopropanoate to obtain the 1-ethyl analogue of compound 
10. The desired product was obtained as an off-white residue, yield = 11%. 1H NMR (600 
MHz, methanol-d4): δ 8.03 (d, J = 10.9 Hz, 1H), 7.94 (s, 1H), 7.45 (s, 1H), 7.36 (d, J = 9.9 
Hz, 1H), 7.30 (s, 1H), 7.25 (s, 1H), 6.92 (d, J = 13.5 Hz, 1H), 3.87 (s, 2H), 2.25 (s, 3H), 1.64 
(s, 3H), 1.10 (s, 3H). MS (ESI): m/z 378.1 [M + 1]+.
1-Cyclopropyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-
methylpyrimidine-2,4(1H,3H)-dione (18).—Compound 18 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-cyclopropylurea and ethyl 2-cyanopropanoate to obtain the 1-cyclopropyl analogue of 
compound 10. The desired product was obtained as an off-white residue, yield = 6%. 1H 
NMR (600 MHz, methanol-d4): δ 8.03 (s, 1H), 7.92 (s, 1H), 7.43 (d, J = 12.3 Hz, 1H), 7.36 
(s, 1H), 7.25 (s, 1H), 7.19 (s, 1H), 6.91 (s, 1H), 2.57 (s, 1H), 2.27 (s, 3H), 1.69 (s, 3H), 0.78–
0.62 (m, 4H). HPLC 99% pure, tR = 4.577 min. HRMS: m/z [M + H]+ calculated for 
C22H20N3O4+ 390.1448, found 390.1456.
1-(Cyclopropylmethyl)-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-
methylpyrimidine-2,4(1H,3H)-dione (19).—Compound 19 was prepared in an 
Martini et al. Page 20













analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-methylcyclopropyllurea and ethyl 2-cyanopropanoate to obtain the 1-
methylcyclopropyl analogue of compound 10. The desired product was obtained as an off-
white residue, yield = 9%. 1H NMR (500 MHz, methanol-d4): δ 8.14 (s, 1H), 7.92 (d, J = 2.2 
Hz, 1H), 7.46 (d, J = 4.8 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.28 (d, J = 2.3 Hz, 1H), 7.23 
(dd, J = 8.3, 2.3 Hz, 1H), 6.92 (dd, J = 2.2, 0.9 Hz, 1H), 3.66 (dd, J = 14.4, 7.2 Hz, 1H), 
3.41–3.35 (m, 2H), 2.25 (s, 3H), 1.66 (s, 3H), 0.23 (dd, J = 4.7, 3.2 Hz, 1H), 0.16 (dd, J = 
4.8, 3.5 Hz, 1H). MS (ESI): m/z 404.2 [M + 1]+.
1-Cyclobutyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-
methylpyrimidine-2,4(1H,3H)-dione (20).—Compound 20 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-cyclobutylurea and ethyl 2-cyanopropanoate to obtain the 1-cyclobutyl analogue of 
compound 10. The desired product was obtained as an off-white residue, yield = 5%. 1H 
NMR (500 MHz, methanol-d4): δ 8.03 (d, J = 5.8 Hz, 1H), 7.94 (d, J = 2.2 Hz, 1H), 7.43 
(dd, J = 5.9, 0.9 Hz, 1H), 7.30 (s, 1H), 7.23 (d, J = 1.4 Hz, 2H), 7.00 (dd, J = 2.2, 1.0 Hz, 
1H), 4.28–4.19 (m, 1H), 3.21–3.11 (m, 2H), 3.11–3.02 (m, 2H), 2.22 (s, 3H), 2.05–1.96 (m, 
2H), 1.61 (s, 3H). MS (ESI): m/z 404.2 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-methyl-1-
propylpyrimidine-2,4(1H,3H)-dione (21).—Compound 21 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-propylurea and ethyl 2-cyanopropanoate to obtain the 1-propyl analogue of 
compound 10. The desired product was obtained as an off-white residue, yield = 19%. 1H 
NMR (500 MHz, methanol-d4): δ 8.04 (d, J = 5.8 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H), 7.47–
7.43 (m, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 7.23 (dd, J = 8.3, 2.4 Hz, 
1H), 6.93 (dd, J = 2.3, 1.0 Hz, 1H), 3.81–3.72 (m, 1H), 3.22 (ddd, J = 13.7, 10.4, 5.5 Hz, 
1H), 2.24 (s, 3H), 1.65 (s, 3H), 1.63–1.55 (m, 1H), 1.50 (d, J = 10.4 Hz, 1H), 0.77 (t, J = 7.4 
Hz, 3H). MS (ESI): m/z 392.2 [M + 1]+.
1-Butyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-
methylpyrimidine-2,4(1H,3H)-dione (22).—Compound 22 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-butylurea and ethyl 2-cyanopropanoate to obtain the 1-butyl analogue of compound 
10. The desired product was obtained as an off-white residue, yield = 15%. 1H NMR (500 
MHz, methanol-d4): δ 8.04 (d, J = 5.9 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 5.9, 
0.9 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.32–7.28 (m, 1H), 7.24 (dd, J = 8.3, 2.4 Hz, 1H), 6.92 
(dd, J = 2.2, 1.0 Hz, 1H), 3.83–3.75 (m, 1H), 3.27 (ddd, J = 13.6, 10.6, 5.3 Hz, 1H), 2.25 (s, 
3H), 1.66 (s, 3H), 1.56 (dd, J = 8.0, 4.9 Hz, 1H), 1.46 (q, J = 6.0 Hz, 1H), 1.19 (dq, J = 17.9, 
8.0, 7.5 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). MS (ESI): m/z 406.2 [M + 1]+.
5-Ethyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-1-
methylpyrimidine-2,4(1H,3H)-dione (23).—Compound 23 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-methylurea and ethyl 2-cyanobutanoate to obtain the 5-ethyl analogue of compound 
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10. The desired product was obtained as an off-white residue, yield = 36%. 1H NMR (600 
MHz, methanol-d4): δ 8.01 (s, 1H), 7.92 (s, 1H), 7.43 (s, 1H), 7.32 (s, 1H), 7.29 (s, 1H), 
7.22 (s, 1H), 6.93 (s, 1H), 3.30 (d, J = 5.3 Hz, 2H), 3.05 (d, J = 3.0 Hz, 3H), 2.23 (d, J = 15.0 
Hz, 3H), 0.94 (s, 3H). MS (ESI): m/z 378.1 [M + 1]+.
1,5-Diethyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-pyrimidine-2,4(1H,
3H)-dione (24).—Compound 24 was prepared in an analogous fashion to the preparation 
of compound 10, using the same procedure but starting with 1-ethylurea and ethyl 2-
cyanobutanoate to obtain the 1,5-diethyl analogue of compound 10. The desired product was 
obtained as an off-white residue, yield = 10%. 1H NMR (600 MHz, methanol-d4): δ 8.03 (s, 
1H), 7.92 (d, J = 2.3 Hz, 1H), 7.43 (d, J = 5.9 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.28 (s, 1H), 
7.22 (d, J = 8.2 Hz, 1H), 6.95 (s, 1H), 3.98 (d, J = 7.2 Hz, 1H), 3.88 (dd, J = 14.0, 7.0 Hz, 
1H), 2.24 (s, 3H), 1.91 (dd, J = 13.7, 7.2 Hz, 1H), 1.25 (t, J = 7.1 Hz, 1H), 1.09 (d, J = 7.7, 
7.0 Hz, 3H), 0.93 (d, J = 7.4 Hz, 3H). MS (ESI): m/z 392.2 [M + 1]+.
1-Cyclopropyl-5-ethyl-6-(4-(furo[3,2-c]pyridin-4-yloxy)-2-
methylphenyl)pyrimidine-2,4(1H,3H)-dione (25).—Compound 25 was prepared in an 
analogous fashion to the preparation of compound 10, using the same procedure but starting 
with 1-cyclopropylurea and ethyl 2-cyanobutanoate to obtain the 5-ethyl, 1-cyclopropyl 
analogue of compound 10. The desired product was obtained as an off-white residue, yield = 
5%. 1H NMR (600 MHz, methanol-d4): δ 8.04 (s, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 7.58 (s, 
1H), 7.43 (s, 1H), 7.38 (s, 1H), 6.90 (s, 1H), 2.53 (s, 1H), 2.29 (s, 3H), 2.02 (s, 1H), 1.32 (s, 
1H), 0.94 (d, J = 10.4 Hz, 3H), 0.75 (s, 2H), 0.68 (s, 2H). MS (ESI): m/z 404.2 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)-3-methylphenyl)-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (26).—To an oven-dried microwavable tube was 
added a stir bar, tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.018 mmol), potassium 
carbonate (25 mg, 0.18 mmol), the previously described intermediate 6-bromo-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (10i) (20 mg, 0.09 mmol), and the known 
intermediate 4-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-
c]pyridine25 (35 mg, 0.10 mmol) in dioxane (1 mL) and water (0.2 mL). Microwave heating 
was then applied to the mixture for 25 min, as described in the General Chemistry 
Procedures. The resulting mixture was subsequently filtered through Celite; the filter was 
washed with several times with ethyl acetate, and the organic filtrate diluted with water and 
extracted three times with ethyl acetate. Brine and saturated NaHCO3 were then used to 
wash the combined organic layers. The organic layers were then dried over anhydrous 
MgSO4 and concentrated in vacuo. The resulting residue was taken up in 2 mL of methanol 
and purified by HPLC using the conditions described previously. This procedure yielded 
compound 26 as a clear oil (9.8 mg, 30%). 1H NMR (500 MHz, methanol-d4): δ 7.93 (d, J = 
2.2 Hz, 1H), 7.55 (t, J = 7.3 Hz, 1H), 7.41–7.38 (m, 1H), 7.34 (s, 1H), 7.31 (d, J = 8.2 Hz, 
1H), 7.25 (dd, J = 8.2, 2.1 Hz, 1H), 7.00 (dd, J = 2.2, 1.0 Hz, 1H), 3.14 (s, 3H), 2.27 (s, 3H), 
1.73 (s, 3H). MS (ESI): m/z 364.1 [M + 1]+.
6-(4-(Furo[3,2-c]pyridin-4-yloxy)phenyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-
dione (27).—Compound 27 was prepared in an analogous fashion to the preparation of 
Martini et al. Page 22













compound 10, using the same procedure but starting with 4-bromophenol to obtain the 
desmethyl intermediate 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)furo[3,2-
c]pyridine. From here, synthesis of the desired product was carried out using the same 
Suzuki coupling methods previously described. The desired product was obtained as an off-
white residue, yield = 16%. 1H NMR (600 MHz, methanol-d4): δ 8.02 (d, J = 5.9 Hz, 1H), 
7.94 (d, J = 2.3 Hz, 1H), 7.43 (d, J = 5.2 Hz, 5H), 7.02–6.99 (m, 1H), 3.13 (s, 3H), 1.73 (s, 
3H). MS (ESI): m/z 350.1 [M + 1]+.
6-(4-Hydroxy-2-methylphenyl)-1,5-dimethylpyrimidine-2,4-(1H,3H)-dione (28).—
To an oven-dried microwavable tube was added a stir bar, 
tetrakis(triphenylphosphine)palladium(0) (25 mg, 0.021 mmol), potassium carbonate (29 
mg, 0.21 mmol), the previously described intermediate 6-bromo-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (10i) (23 mg, 0.11 mmol), and commercially 
available (4-hydroxyphenyl)boronic acid (18 mg, 0.12 mmol) in dioxane (1 mL) and water 
(0.2 mL). Microwave heating was then applied to the mixture for 25 min, as described in the 
General Chemistry Procedures. The resulting mixture was subsequently filtered through 
Celite; the filter washed with several times with ethyl acetate, and the organic filtrate diluted 
with water and extracted three times with ethyl acetate. Brine and saturated NaHCO3 were 
then used to wash the combined organic layers. The organic layers were then dried over 
anhydrous MgSO4 and concentrated in vacuo. The resulting residue was taken up in 2 mL of 
methanol and purified by HPLC using the conditions described previously. This procedure 
yielded compound 28 as a beige residue, yield = 46%. 1H NMR (500 MHz, methanol-d4): δ 
7.00 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 2.4 Hz, 1H), 6.80 (dd, J = 8.3, 2.5 Hz, 1H), 3.00 (s, 
3H), 2.13 (s, 3H), 1.61 (s, 3H). MS (ESI): m/z 247.1 [M + 1]+.
6-(4-Methoxy-2-methylphenyl)-1,5-dimethylpyrimidine-2,4-(1H,3H)-dione (29).—
To an oven-dried microwavable tube was added a stir bar, 
tetrakis(triphenylphosphine)palladium(0) (25 mg, 0.021 mmol), potassium carbonate (29 
mg, 0.21 mmol), the previously described intermediate 6-bromo-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (10i) (23 mg, 0.11 mmol), and commercially 
available (4-methoxyphenyl)boronic acid (20 mg, 0.12 mmol) in dioxane (1 mL) and water 
(0.2 mL). Microwave heating was then applied to the mixture for 25 min, as described in the 
General Chemistry Procedures. The resulting mixture was subsequently filtered through 
Celite; the filter was washed with several times with ethyl acetate, and the organic filtrate 
diluted with water and extracted three times with ethyl acetate. Brine and saturated NaHCO3 
were then used to wash the combined organic layers. The organic layers were then dried 
over anhydrous MgSO4 and concentrated in vacuo. The resulting residue was taken up in 2 
mL of methanol and purified by HPLC using the conditions described previously. This 
procedure yielded compound 29 as a beige residue, yield = 50%. 1H NMR (500 MHz, 
methanol-d4): δ 7.12 (d, J = 8.3 Hz, 1H), 6.99 (d, J = 2.5 Hz, 1H), 6.96 (dd, J = 8.4, 2.6 Hz, 
1H), 3.87 (s, 3H), 3.00 (s, 3H), 2.19 (s, 3H), 1.60 (s, 3H). MS (ESI): m/z 261.1 [M + 1]+.
1,5-Dimethyl-6-(2-methyl-4-(pyridin-2-yloxy)phenyl)pyrimidine-2,4(1H,3H)-
dione (30).—The intermediate 2-(4-bromo-3-methylphenoxy)pyridine (174.1 mg, 0.66 
mmol) was prepared using 4-bromo-3-methylphenol (120 mg, 0.64 mmol) and 2-
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bromopyridine (92 mg, 0.58 mmol) using the same conditions previously described.25,68 2-
(4-Bromo-3-methylphenoxy)pyridine (174.1 mg, 0.66 mmol) was then converted to the 
boronic ester intermediate 2-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)-pyridine (227 mg, 0.73 mmol, 100%) with the same conditions described 
previously. Compound 30 was prepared using the same procedure as preparing compound 10 
starting with 2-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine 
(23 mg, 0.07 mmol). The title compound was obtained as a beige residue, yield = 33%. 1H 
NMR (500 MHz, methanol-d4): δ 7.91 (t, J = 7.7 Hz, 1H), 7.27 (d, J = 8.3 Hz, 2H), 7.20 (s, 
2H), 7.14 (d, J = 8.6 Hz, 2H), 3.07 (s, 3H), 2.23 (d, J = 1.8 Hz, 3H), 1.68–1.64 (m, 3H). MS 
(ESI): m/z 324.1 [M + 1]+.
6-(4-((4-Methoxypyridin-2-yl)oxy)-2-methylphenyl)-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (31).—Starting from 2-chloro-4-
methoxypyridine and 4-bromo-3-methylphenol, compound 31 was prepared according to the 
same procedures and synthetic route as 30. The title compound was obtained as a beige 
residue, yield = 49%. 1H NMR (500 MHz, methanol-d4): δ 7.32–7.28 (m, 1H), 7.24 (s, 1H), 
7.18 (d, J = 8.4 Hz, 1H), 6.93 (s, 1H), 6.69 (s, 1H), 3.98–3.93 (m, 3H), 3.08–3.03 (m, 3H), 
2.24 (s, 3H), 1.68–1.62 (m, 3H). MS (ESI): m/z 354.1 [M + 1]+.
1,5-Dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)-
oxy)phenyl)pyrimidine-2,4(1H,3H)-dione (32).—Starting from 2-bromo-3-
(trifluoromethyl)pyridine and 4-bromo-3-methylphenol, compound 32 was prepared 
according to the same procedures and synthetic route as 30. The title compound was 
obtained as a beige residue, yield = 42%. 1H NMR (500 MHz, methanol-d4): δ 8.36 (dd, J = 
4.8, 1.9 Hz, 1H), 8.22 (d, J = 7.4 Hz, 1H), 7.34–7.30 (m, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.19 
(dd, J = 8.3, 2.5 Hz, 1H), 3.07 (s, 3H), 2.25 (s, 3H), 1.67 (s, 3H). MS (ESI): m/z 392.1 [M 
+ 1]+.
2-(4-(3,5-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3-
methylphenoxy)-4-methoxynicotinonitrile (33).—Starting from 2-chloro-4-
methoxynicotinonitrile and 4-bromo-3-methylphenol, compound 33 was prepared according 
to the same procedures and synthetic route as 30. The title compound was obtained as a 
beige residue, yield 48%. 1H NMR (500 MHz, Methanol-d4) δ 8.23 (d, J = 6.1 Hz, 1H), 7.32 
(s, 1H), 7.30 (s, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.05 (d, J = 6.1 Hz, 1H), 4.13 (s, 3H), 3.07 (s, 
3H), 2.26 (s, 3H), 1.66 (s, 3H). MS (ESI) m/z 379.1 [M + 1]+.
6-(4-((4-Chloro-3-(trifluoromethyl)pyridin-2-yl)oxy)-2-methyl-phenyl)-1,5-
dimethylpyrimidine-2,4(1H,3H)-dione (34).—Starting from 2,4-dichloro-3-
(trifluoromethyl)pyridine and 4-bromo-3-methylphenol, compound 34 was prepared 
according to the same procedures and synthetic route as 30. The title compound was 
obtained as a beige residue, yield = 16%. 1H NMR (500 MHz, methanol-d4): δ 8.42 (d, J = 
5.8 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.99 
(d, J = 5.8 Hz, 1H), 3.08–3.04 (m, 3H), 2.27 (s, 3H), 1.68–1.64 (m, 3H). MS (ESI) m/z 
426.1 [M + 1]+.
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dimethylpyrimidine-2,4(1H,3H)-dione (35).—Starting from 2-chloro-4-methoxy-3-
(trifluoromethyl)pyridine and 4-bromo-3-methylphenol, compound 35 was prepared 
according to the same procedures and synthetic route as 30. The title compound was 
obtained as a beige residue, yield = 52%. 1H NMR (600 MHz, chloroform-d): δ 8.40 (s, 
1H), 8.21 (s, 1H), 7.14 (s, 1H), 7.13 (s, 1H), 6.77 (d, J = 5.7 Hz, 1H), 4.01 (s, 3H), 3.06 (s, 
3H), 2.20 (s, 3H), 1.69 (s, 3H). HPLC 99% pure, tR = 4.753 min. HRMS m/z [M + H]+ 
calculated for C20H19F3N3O4+ 4 422.1322, found 422.1321.
1,5-Dimethyl-6-(2-methyl-4-((2-methylfuro[3,2-c]pyridin-4-yl)-
oxy)phenyl)pyrimidine-2,4(1H,3H)-dione (36).—Starting from 4-chloro-2-
methylfuro[3,2-c]pyridine and 4-bromo-3-methylphenol, compound 36 was prepared 
according to the same procedures and synthetic route as 30. The title compound was 
obtained as a beige residue, yield = 32%. 1H NMR (500 MHz, methanol-d4): δ 8.05 (s, 1H), 
7.42 (d, J = 5.6 Hz, 1H), 7.33–7.29 (m, 2H), 7.23 (dd, J = 8.3, 2.4 Hz, 1H), 6.45–6.43 (m, 
1H), 3.08 (s, 3H), 2.53 (s, 3H), 2.25 (s, 3H), 1.67 (s, 3H). HPLC 99% pure, tR = 4.672 min. 
HRMS m/z [M + H]+ calculated for C21H20N3O4+ 378.1448, found 378.1442.
1,5-Dimethyl-6-(2-methyl-4-((1-methyl-1H-pyrrolo[3,2-c]pyridin-4-
yl)oxy)phenyl)pyrimidine-2,4(1H,3H)-dione (37).—Starting from 4-chloro-1-
methyl-1H-pyrrolo[3,2-c]pyridine and 4-bromo-3-methylphenol, compound 37 was prepared 
according to the same procedures and synthetic route as 30. The title compound was 
obtained as a beige residue, yield = 50%. 1H NMR (500 MHz, methanol-d4): δ 8.04 (s, 1H), 
7.72 (d, J = 6.4 Hz, 1H), 7.52 (d, J = 3.3 Hz, 1H), 7.47 (d, J = 2.2 Hz, 1H), 7.44–7.38 (m, 
2H), 6.12 (d, J = 3.4 Hz, 1H), 3.99 (s, 3H), 3.09 (s, 3H), 2.28 (s, 3H), 1.68 (s, 3H). HPLC 
99% pure, tR = 3.834 min. HRMS: m/z [M + H]+ calculated for C21H21N4O3+ 377.1608, 
found 377.1610.
6-(4-(Isoquinolin-1-yloxy)-2-methylphenyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-
dione (38).—Starting from 1-chloroisoquinoline and 4-bromo-3-methylphenol, compound 
38 was prepared according to the same procedures and synthetic route as 30. The title 
compound was obtained as a beige residue, yield = 40%. 1H NMR (500 MHz, methanol-d4): 
δ 8.46 (d, J = 8.3 Hz, 1H), 7.95 (dd, J = 14.2, 6.9 Hz, 2H), 7.89–7.83 (m, 1H), 7.78–7.72 (m, 
1H), 7.54 (d, J = 5.8 Hz, 1H), 7.36–7.26 (m, 3H), 3.11 (d, J = 2.7 Hz, 3H), 2.29–2.25 (m, 
3H), 1.69 (d, J = 2.5 Hz, 3H). MS (ESI): m/z 374.1 [M + 1]+.
1,5-Dimethyl-6-(2-methyl-4-(thieno[3,2-c]pyridin-4-yloxy)-
phenyl)pyrimidine-2,4(1H,3H)-dione (39).—Starting from 4-chlorothieno[3,2-
c]pyridine and 4-bromo-3-methylphenol, compound 39 was prepared as a white solid 
according to the same procedures and synthetic route as 30. The title compound was 
obtained as a beige residue, yield = 29%. 1H NMR (500 MHz, methanol-d4): δ 7.96 (d, J = 
5.7 Hz, 1H), 7.78 (d, J = 5.5 Hz, 1H), 7.75 (dd, J = 5.7, 0.9 Hz, 1H), 7.48 (s, 1H), 7.31 (dd, J 
= 5.4, 3.0 Hz, 2H), 7.25 (dd, J = 8.3, 2.4 Hz, 1H), 3.09 (s, 3H), 2.26 (s, 3H), 1.68 (s, 3H). 
MS (ESI): m/z 380.1 [M + 1]+.
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phenyl)pyrimidine-2,4(1H,3H)-dione (40).—Starting from 7-chlorothieno[2,3-
c]pyridine and 4-bromo-3-methylphenol, compound 40 was prepared according to the same 
procedures and synthetic route as 30. The title compound was obtained as a beige residue, 
yield = 49%. 1H NMR (600 MHz, chloroform-d): δ 8.54 (s, 1H), 8.07 (s, 1H), 7.76 (d, J = 
5.3 Hz, 1H), 7.50 (s, 1H), 7.43 (d, J = 5.3 Hz, 1H), 7.28 (d, J = 5.4 Hz, 1H), 7.15 (d, J = 8.2 
Hz, 1H), 3.06 (s, 3H), 2.20 (s, 3H), 1.69 (s, 3H). HPLC 99% pure, tR = 4.775 min. HRMS: 
m/z [M + H]+ calculated for C20H18N3O3S+ 380.1063, found 380.1064.
Experimental Procedures for In Vitro Pharmacology Assays.
General Procedures.—The protocols that were used to carry out the cAMP biosensor 
and bioluminescent resonance energy transfer (BRET) assays are provided below.
D1R GS-Mediated GS-cAMP Accumulation Assay.—D1R-mediated accumulation of 
cAMP was measured in HEK293T cells cotransfected with human D1 and the cAMP 
biosensor GloSensor-22F (Promega) in a ratio of 1:15. The next day 50 000 cells per well in 
cMEM + 2% dialyzed FBS were plated in PDK-treated 96 well plates and incubated 
overnight. The next day media was removed and cells were washed with 100 μL of HBSS + 
HEPES and 25 μL of luciferin (Gold Biotechnology) was added per well. Plates were 
incubated for 2 h at room temperature. Compounds were prepared in HBSS/HEPES/0.01% 
BSA/0.1% ascorbate at 10× and 10 μL per well was added. After 15 min, cAMP 
accumulation was measured using a BMG Clariostar plate reader. Net response was 
determined by subtracting the reading without compound from the reading with compound 
added. Values were normalized to percent of maximum dopamine response and analyzed 
using GraphPad Prism 7 (Graphpad Software, Inc., San Diego, CA).
Bioluminescence Resonance Energy Transfer (BRET) β-Arrestin2 Assay.—To 
measure D1R mediated recruitment of β-arrestin2, HEK293T cells were cotransfected with 
human D1 fused with C-terminal Renilla luciferase (RLuc8) and N-terminal Venus β-
arrestin 2 in a ratio of 1:20. The next day transfected cells were plated at 50 000 cells per 
well into 96-well PDK-coated plates in 100 μL of cMEM + 2% dialyzed FBS and incubated 
overnight. The next day media was replaced with 80 μL of HBSS, 20 mM HEPES, and 10 
μL of coelentrazine h (Nanolight Technology, 5 μM final concentration) was added. 
Compounds were prepared in HBSS/HEPES/.01%BSA/.01% ascorbate at 10× and 10 μL per 
well was added. Plates were incubated 15 min and then the luminescence at 485 nm and 
fluorescence at 530 nm were both measured for 1 s per well using a BMG Clariostar plate 
reader. The ratio of eYFP/RLUC was calculated per well and the net BRET ratio was 
determined by subtracting the net BRET without drug from the net BRET in wells 
containing drug. The data were normalized to the percent of the maximal response with 
dopamine stimulation. The net BRET was plotted as a function of compound concentration 
using Graphpad Prism 7 (Graphpad Software Inc., San Diego, CA).
Bias Calculation.—The Black and Leff operational model, in which τ is agonist efficacy 
and KA is the equilibrium dissociation constant, was implemented to determine the 
transduction coefficients (log (τ/KA)). Transduction coefficients for GS activity and β-
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arrestin2 recruitment were calculated and averaged across experiments, using dopamine as 
the full agonist reference. The method outlined by Kenakin et al. was used in the calculation 
of bias factors, where the Δlog(τ/KA) was calculated relative to the reference and the 
ΔΔlog(τ/KA) was calculated by subtracting the GS from β-arrestin2 transduction coefficient.
83 This analysis was performed in Graphpad Prism 7.0.
Radioligand Binding Affinity Assays.—Compounds were screened in primary 
radioligand binding assays to determine if they reached a certain affinity threshold 
(measured as% inhibition) across a wide panel of over 30 other potential targets. 
Compounds with a mean inhibition greater than 50% across four determinations are 
considered to have surpassed the affinity threshold and were subsequently examined in 
secondary radioligand binding assays for Ki determination at each receptor over the 
threshold. Primary and secondary assays were conducted using the same protocols and 
procedures that have been previously described.74 Additional information and details 
concerning assay methods can be found online at https://pdspdb.unc.edu/pdspWeb/?
site=assays.
Experimental Procedures for In Vivo Pharmacokinetic Studies.
Compounds 10 and 35 were taken up in 5% NMP, 5% Solutol HS-15, 30% PEG-400, and 
60% normal saline for formulation. A formulated solution of compounds 10 and 35 were 
each administered intraperitoneally at a 50 mg/kg dose to a designated group of nine male 
Swiss Albino mice. Approximately, 60 μL of blood were acquired from a set of three mice 
within the group at 0.5, 1.5, and 4 h under light isoflurane anesthesia. Blood samples were 
centrifuged to harvest plasma. The plasma was then stored at −70 ± 10 °C until analysis. 
Three mice were sacrificed immediately after blood collection to obtain brain samples for 
each time point at 0.5, 1.5, and 4 h. Brain samples were homogenized using ice-cooled 
phosphate buffer saline (pH 7.4) in a ratio of 2 (buffer): 1(brain). Homogenates were stored 
below −70 ± 10 °C until analysis. Total homogenate volume was three times the brain 
weight. Pharmacokinetic analysis was conducted using the plasma and brain concentration–
time data of compounds 10 and 35. The NCA module of Phoenix WinNonlin (version 7.0) 
was used to perform the pharmacokinetic analysis. A fit-for-purpose LCMS/MS method was 
used to quantify plasma and brain samples (LLOQ = 1.01 ng/mL for plasma and 3.03 ng/g 
for brain).
Experimental Procedures for In Vivo Behavioral and Locomotion Studies in 6-
Hydroxydopamine (6-OHDA)-Lesioned Animals.
Animals.—Male and female C57Bl/6 mice were used in these experiments. They were 
housed 3–5 animals per cage on a 14: 10 h light: dark cycle (lights on 07:00 h), with food 
and water ad libitum, and they were tested at 4–6 months of age. Experiments took place 
between 09:00 and 17:00 h.
Drugs.—SKF81297 (Tocris) was dissolved in sterile saline and compound 10 in 5% NMP, 
5% Kolliphor, and 90% sterile saline. Drugs were injected i.p., in a volume of 5 mL/kg. 6-
Hydroxydopamine hydrobromide (6-OHDA, Sigma) was dissolved in 0.02% ascorbic acid 
to a concentration of 3.6 mg/mL.
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Surgeries.—Mice were anesthetized with a mixture of ketamine/zylazine 100/10 mg/kg 
and placed in the stereotaxic frame. A hole was made in the right side of the skull at 
coordinates −0.8, L 1.1 relative to Bregma. A 2 μL syringe was lowered at −4.75 mm below 
skull and 1 μL of 6-OHDA was delivered over 5 min into the right medial forebrain bundle 
(Paxinos, 2007). The needle remained in place for 5 additional minutes and was then slowly 
withdrawn. Animals were allowed to recover for 15–19 days after surgery until their body 
weights stabilized. During this time, they received high fat diets and condensed milk 
supplements. Sterile 5% dextrose solution was administered subcutaneously daily to prevent 
dehydration.
Apparatus.—Clear plastic arenas 20 cm in diameter were placed in the open field 
apparatus (Omnitech Electronics Inc., Columbus, OH) measuring 42 × 42 × 40. Overhead 
cameras recorded videos of the sessions. These videos were analyzed off-line by Ethovision 
software (Noldus) as distance moved by the center point of the mouse’s body or 
contralateral rotations around center point (away from lesioned side).
Procedure.—After recovery, mice were given vehicle, SKF 81297 (5 mg/kg), or 
compound 10 (5 mg/kg) and immediately placed in the plastic arenas for 90 min. These 
experiments were performed in accordance with all national and local guidelines and 
regulations.
Statistics.—Data are means and SEMs. Two-way ANOVA was used for analysis of time as 
a within-subject factor and treatment as a between-subject factor. In instances of significant 
interactions (P < 0.05), Bonferroni posthoc tests were subsequently applied.
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Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
GPCR G protein-coupled receptor
SFSR structure–functional selectivity relationship
D1R dopamine D1 receptor
GS stimulatory G protein
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cAMP cyclic adenosine monophosphate
RHS right-hand side
LHS left-hand side
BRET bioluminescence resonance energy transfer
D2R dopamine D2 receptor
D3R dopamine D3 receptor
D4R dopamine D4 receptor
D5R dopamine D5 receptor
5-HT 5-hydroxytryptamine
H1 histamine receptor 1
H2 histamine receptor 2
M1 muscarinic receptor 1
M2 muscarinic receptor 2
M3 muscarinic receptor 3
MOR mu opioid receptor
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Iterative strategy for generating novel noncatechol analogues of compound 1 with increased 
agonist activity at D1R and diverse functional selectivity profiles.
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First iteration of analogues (2–5) derived from compound 1 to explore the effects of nitrogen 
methylation and addition of a carbonyl oxygen and an additional nitrogen into the RHS 
heterocycle. Full concentration–response curves for the first iteration of RHS analogues 
measured using the GloSensor assay for GS pathway activation (A) and the BRET assay for 
β-arrestin2 recruitment (B) as a percentage of the maximal dopamine (DA) response. Curves 
represent at least three independent experiments performed in triplicate. Data points 
represent the mean ± SEM.
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Second iteration of analogues (6–9) derived from compound 5 were designed to explore the 
effects of carbonyl oxygen and amine substituents on the RHS heterocycle. Full 
concentration–response curves for the second iteration of RHS analogues measured using 
the GloSensor assay for GS pathway activation (A) and the BRET assay for β-arrestin2 
recruitment (B) as a percentage of the maximal dopamine (DA) response. Curves represent 
at least three independent experiments performed in triplicate. Data points represent the 
mean ± SEM.
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Third iteration of analogues (10–13) derived from compound 9 to explore the effects of 
heteroatom positioning and methylation of the RHS heterocycle. Full concentration–
response curves for the third iteration of RHS analogues measured using the GloSensor 
assay for GS pathway activation (A) and the BRET assay for β-arrestin2 recruitment (B) as a 
percentage of the maximal dopamine (DA) response. Curves represent at least three 
independent experiments performed in triplicate. Data points represent the mean ± SEM.
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Fourth iteration of analogues (14–16) derived from compound 10 to explore the effects of 
alkylation of the 3-position nitrogen on the RHS heterocycle. Full concentration–response 
curves for the fourth iteration of RHS analogues measured using the GloSensor assay for GS 
pathway activation (A) and the BRET assay for β-arrestin2 recruitment (B) as a percentage 
of the maximal dopamine (DA) response. Curves represent at least three independent 
experiments performed in triplicate. Data points represent the mean ± SEM.
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Fifth iteration of analogues (17–22) derived from compound 10 to explore the effects of 
alkylation of the 1-position nitrogen on the RHS heterocycle. Full concentration–response 
curves for the fifth iteration of RHS analogues measured using the GloSensor assay for GS 
pathway activation (A) and the BRET assay for β-arrestin2 recruitment (B) as a percentage 
of the maximal dopamine (DA) response. Curves represent at least three independent 
experiments performed in triplicate. Data points represent the mean ± SEM.
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Sixth iteration of analogues (23–25) derived from compound 10 to explore the effects of 
ethylation of the 5-position nitrogen on the RHS heterocycle. Full concentration–response 
curves for the sixth iteration of RHS analogues measured using the GloSensor assay for GS 
pathway activation (A) and the BRET assay for β-arrestin2 recruitment (B) as a percentage 
of the maximal dopamine (DA) response. Curves represent at least three independent 
experiments performed in triplicate. Data points represent the mean ± SEM.
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Compounds 26 and 27 were derived from compound 10 and were designed to explore the 
importance of the methyl substituent and its position on the middle phenyl ring of the 
noncatechol scaffold in the presence of the highly active pyrimidine dione RHS moiety. Full 
concentration–response curves for the middle phenyl ring analogues measured using the 
GloSensor assay for GS pathway activation (A) and the BRET assay for β-arrestin2 
recruitment (B) as a percentage of the maximal dopamine (DA) response. Curves represent 
at least three independent experiments performed in triplicate. Data points represent the 
mean ± SEM.
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First iteration of analogues (28–30) derived from compound 10 to explore the effects of the 
presence of an LHS heterocycle on the noncatechol scaffold. Full concentration–response 
curves for the first iteration of LHS analogues measured using the GloSensor assay for GS 
pathway activation (A) and the BRET assay for β-arrestin2 recruitment (B) as a percentage 
of the maximal dopamine (DA) response. Curves represent at least three independent 
experiments performed in triplicate. Data points represent the mean ± SEM.
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Second iteration of analogues (31–34) derived from compound 30 were designed to explore 
the effects of substituents on the 3- and 4-positions of the LHS pyridine heterocycle. The 
interesting trends noted in this mini-series led to the subsequent development of 35. Full 
concentration–response curves for the second iteration of LHS analogues measured using 
the GloSensor assay for GS pathway activation (A) and the BRET assay for β-arrestin2 
recruitment (B) as a percentage of the maximal dopamine (DA) response. Curves represent 
at least three independent experiments performed in triplicate. Data points represent the 
mean ± SEM.
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Compounds 36–40 were derived from compound 10 and were designed to explore the 
effects of methylation, heteroatom type, and heteroatom position within the LHS moiety. 
Full concentration–response curves for the analogues exploring the LHS pyridofuran moiety 
measured using the GloSensor assay for GS pathway activation (A) and the BRET assay for 
β-arrestin2 recruitment (B) as a percentage of the maximal dopamine (DA) response. Curves 
represent at least three independent experiments performed in triplicate. Data points 
represent the mean ± SEM.
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Summary of the full concentration–response curves of structurally related analogue 
compounds of the noncatechol scaffold that display dramatically different functional 
selectivity profiles, as measured using the GloSensor assay for GS pathway activation (GS-
cAMP) and the BRET assay for β-arrestin2 (β-arr2) recruitment as a percentage of the 
maximal dopamine (DA) response. Dopamine (A) is a potent, balanced full agonist of both 
signaling pathways. Compound 10 (B) is a highly potent full agonist with balanced activity 
relative to dopamine. Compound 35 (C) is a potent partial agonist that displays complete 
GS-bias, a similar profile shared with compounds 36 (D) and 37 (E). Compound 40 (F) is a 
potent agonist of both signaling pathways. Data points represent the mean concentrations ± 
SEM from at least three independent experiments.
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Mouse pharmacokinetic profile of compounds 10 (A) and 35 (B) in the plasma and brain. 
Both compounds were injected into the peritoneum at 50 mg/kg. Concentrations in the brain 
and plasma were quantified at 0.5, 1.5, and 4.0 h after administration. Experiments were 
carried out in biological triplicates, with points representing mean concentrations ± SEM.
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Compound 10 displays a potent antiparkinsonian-like activity in a motor activity study in 6-
OHDA-lesioned mice. 6-OHDA-lesioned mice were given the vehicle, 10 (5 mg/kg), or 
SKF81297 (5 mg/kg) intraperitoneally and monitored for 90 min. (A) Locomotor activities 
are shown as binned 10 min intervals. The repeated measures analysis of variance 
(RMANOVA) are provided: [time F(8, 224) = 3.17, p = 0.0020; treatment F(2, 28) = 12.42, 
p = 0.0001; time by treatment F(16, 224) = 7.825, p < 0.0001]. (B) Cumulative locomotor 
activities from the 0–60 and 61–90 min intervals. A RMANOVA found: [prepost F(1, 28) = 
89.06, p < 0.0001; treatment F(2, 28) = 12.42, p = 0.0001; prepost by treatment F(2, 28) = 
17.42, p < 0.0001]. (C) Contralateral rotation activities are shown as binned 10 min 
intervals. The repeated measures analysis of variance (RMANOVA) are provided: [time F(8, 
224) = 5.23, p < 0.0001; treatment F(2, 28) = 5.482, p = 0.0098; time by treatment F(16, 
224) = 4.212, p < 0.0001]. (D) Cumulative contralateral rotation activities from the 0–60 
min and 61–90 min intervals. A RMANOVA found: [prepost F(1, 28) = 18.52, p = 0.0002; 
treatment F(2, 28) = 5.482, p = 0.0098; prepost by treatment F(2, 28) = 6.013, p = 0.0067]. 
N = 10–11 mice/group; Bonferroni-corrected pairwise comparisons—*p < 0.05, **p < 
0.0001.
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Scheme 1. Synthesis of the First, Second, and Third Iterations of Compounds for Exploring the 
RHS Heterocyclic Moietya
aReagents and conditions: (a) Cs2CO3, DMSO, 125 °C, 48 h; (b) Pd(dppf)Cl2, KOAc, 
B2(pin)2, dioxane, 80 °C, 18 h; (c) Pd(PPh3)4, K2CO3, dioxane, H2O, 120 °C, 25 min; (d) 
NaOMe, reflux, 24 h; (e) NaNO2, CuBr2, rt, 66 h; (f) p-TsOH, THF, reflux, 24 h; (g) 
MeB(OH)2, Pd(dppf)Cl2, Cs2CO3, dioxane, H2O, 110 °C, 2 h.
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Scheme 2. Synthesis of the First and Second Iterations of Compounds for Exploring the LHS 
Heterocyclic Moietya
aReagents and conditions: (a) Pd(PPh3)4, K2CO3, dioxane, H2O, 120 °C, 25 min; (b) 
Cs2CO3, DMSO, 125 °C, 48 h; (c) Pd(dppf)Cl2, KOAc, B2(pin)2, dioxane, 80 °C, 18 h.
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Table 1.
Radioligand Binding Affinities of Compounds 10, 18, 35, 36, 37, and 40 at Select GPCRs, Ion Channels, and 
Transporters
a
binding affinity Ki (nM)
receptor 10 18 35 36 37 40
D1 5.7 10 70 93 14 5.1
D2 NC NC NC NC NC NC
D3 NC NC NC NC NC NC
D4 NC NC NC NC NC NC
D5 6.7 15 171 185 90 53
5-HT1A NC NC NC NC NC NC
5-HT1B NC NC NC NC NC NC
5-HT1D NC NC NC NC NC NC
5-HT1E NC NC NC NC NC NC
5-HT2A NC NC NC NC NC NC
5-HT2B NC NC NC NC NC NC
5-HT3 NC NC NC NC NC NC
5-HT4 NC NC NC NC NC NC
5-HT5A NC NC NC NC NC NC
5-HT6 NC NC NC NC NC NC
5-HT7A NC NC NC NC NC NC
Alpha1A NC NC NC NC NC NC
Alpha1B NC NC NC NC NC NC
Alpha2A NC NC 6900 NC NC NC
Beta1 NC NC NC NC NC NC
Beta2 NC NC NC NC NC NC
MOR NC NC NC NC NC NC
KOR NC NC NC NC NC NC
M1 NC NC NC NC NC NC
M2 NC 7700 6900 NC NC NC
M3 NC NC NC NC 4200 4600
Sigma1 NC NC NC NC NC NC
H1 NC NC NC NC NC NC
H2 NC NC NC NC NC NC
DAT NC NC NC NC NC NC
SERT NC NC NC NC NC NC
a
Ki values represent the average of at least three triplicate experiments. SEM < ±20%. NC: Not calculated because minimum affinity threshold was 
not reached in primary binding assay.
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